<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1201233088
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cosentyx 300 mg per 2 ml Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SECUKINUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4033.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AC10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cosentyx contains the active substance secukinumab. Secukinumab is a monoclonal antibody which belongs to a group of medicines called interleukin (IL) inhibitors. This medicine works by neutralising the activity of a protein called IL‑17A, which is present at increased levels in diseases such as psoriasis, hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.</p><p>&nbsp;</p><p>Cosentyx is used for the treatment of the following inflammatory diseases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plaque psoriasis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hidradenitis suppurativa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriatic arthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Axial spondyloarthritis, including ankylosing spondylitis (radiographic axial spondyloarthritis) and non-radiographic axial spondyloarthritis</p><p><u>&nbsp;</u></p><p><strong>Plaque psoriasis</strong></p><p>Cosentyx is used to treat a skin condition called &ldquo;plaque psoriasis&rdquo;, which causes inflammation affecting the skin. Cosentyx reduces the inflammation and other symptoms of the disease. Cosentyx is used in adults, adolescents and children (6&nbsp;years of age and older) with moderate to severe plaque psoriasis.</p><p>&nbsp;</p><p>Using Cosentyx in plaque psoriasis will benefit you by leading to improvements of skin clearance and reducing your symptoms such as scaling, itching and pain.</p><p>&nbsp;</p><p><strong>Hidradenitis suppurativa</strong></p><p>Cosentyx is used to treat a condition called hidradenitis suppurativa, also sometimes called acne inversa</p><p>or Verneuil&rsquo;s disease. This condition is a chronic and painful inflammatory skin disease. Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It commonly affects specific areas of the skin, such as under the breasts, the armpits, inner thighs, groin and buttocks. Scarring may also occur in affected areas.</p><p>&nbsp;</p><p>Cosentyx can reduce the number of nodules and abscesses you have and the pain that is often associated with the disease. If you have hidradenitis suppurativa you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx.</p><p>&nbsp;</p><p>Cosentyx is used in adults with hidradenitis suppurativa and can be used alone or with antibiotics.</p><p>&nbsp;</p><p><strong>Psoriatic arthritis</strong></p><p>Cosentyx is used to treat a condition called &ldquo;psoriatic arthritis&rdquo;. The condition is an inflammatory disease of the joints, often accompanied by psoriasis. If you have active psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of active psoriatic arthritis, improve physical function and slow down the damage to the cartilage and bone of the joints involved in the disease.</p><p>&nbsp;</p><p>Cosentyx is used in adults with active psoriatic arthritis and can be used alone or with another medicine called methotrexate.</p><p>&nbsp;</p><p>Using Cosentyx in psoriatic arthritis will benefit you by reducing the signs and symptoms of the disease, slowing down the damage to the cartilage and bone of the joints and improving your ability to do normal daily activities.</p><p>&nbsp;</p><p><strong>Axial spondyloarthritis, including ankylosing spondylitis (radiographic axial spondyloarthritis) and non-radiographic axial spondyloarthritis</strong></p><p>Cosentyx is used to treat conditions called &ldquo;ankylosing spondylitis&rdquo; and &ldquo;non-radiographic axial spondyloarthritis&rdquo;. These conditions are inflammatory diseases primarily affecting the spine which cause inflammation of the spinal joints. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of the disease, reduce inflammation and improve your physical function.</p><p>&nbsp;</p><p>Cosentyx is used in adults with active ankylosing spondylitis and active non-radiographic axial spondyloarthritis.</p><p>&nbsp;</p><p>Using Cosentyx in ankylosing spondylitis and non-radiographic axial spondyloarthritis will benefit you by reducing the signs and symptoms of your disease and improving your physical function.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Cosentyx:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic </strong>to secukinumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>If you think you may be allergic, ask your doctor for advice before using Cosentyx.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have an active infection</strong> which your doctor thinks is important.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, nurse or pharmacist before using Cosentyx:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you currently have an infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have long‑term or repeated infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have tuberculosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an inflammatory disease affecting your gut called Crohn&rsquo;s disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an inflammation of your large intestine called ulcerative colitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had a vaccination or if you are due to have a vaccination during treatment with Cosentyx.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are receiving any other treatment for psoriasis, such as another immunosuppressant or phototherapy with ultraviolet (UV) light.</p><p>&nbsp;</p><p><strong>Inflammatory bowel disease (Crohn&rsquo;s disease or ulcerative colitis)</strong></p><p>Stop using Cosentyx and tell your doctor or seek medical help immediately if you notice abdominal cramps and pain, diarrhoea, weight loss, blood in the stool or any other signs of bowel problems.</p><p>&nbsp;</p><p><strong>Look out for infections and allergic reactions</strong></p><p>Cosentyx can potentially cause serious side effects, including infections and allergic reactions. You must look out for signs of these conditions while you are taking Cosentyx.</p><p>&nbsp;</p><p>Stop using Cosentyx and tell your doctor or seek medical help immediately if you notice any signs indicating a possible serious infection or an allergic reaction. Such signs are listed under &ldquo;Serious side effects&rdquo; in section&nbsp;4.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Cosentyx is not recommended for children younger than 6&nbsp;years of age with plaque psoriasis because it has not been studied in this age group.</p><p>&nbsp;</p><p>Cosentyx is not recommended for children and adolescents (under 18&nbsp;years of age) in other indications because it has not been studied in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Cosentyx</strong></p><p>Tell your doctor or pharmacist:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking, have recently taken or might take any other medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had or are due to have a vaccination. You should not be given certain types of vaccines (live vaccines) while using Cosentyx.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pregnancy, breast‑feeding and fertility</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is preferable to avoid the use of Cosentyx in pregnancy. The effects of this medicine in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Cosentyx and for at least 20&nbsp;weeks after the last Cosentyx dose.</p><p>Talk to your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you are breast‑feeding or are planning to breast‑feed. You and your doctor should decide if you will breast-feed or use Cosentyx. You should not do both. After using Cosentyx you should not breast‑feed for at least 20&nbsp;weeks after the last dose.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Cosentyx is unlikely to influence your ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Cosentyx is given via injection under your skin (known as a subcutaneous injection). You and your doctor should decide if you should inject Cosentyx yourself.</p><p>&nbsp;</p><p>It is important not to try to inject yourself until you have been trained by your doctor, nurse or pharmacist. A caregiver may also give you your Cosentyx injection after proper training.</p><p>&nbsp;</p><p>For detailed instructions on how to inject Cosentyx, see &ldquo;Instructions for use of the Cosentyx 300&nbsp;mg UnoReady pen&rdquo; at the end of this leaflet.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>How much Cosentyx is given and for how long</strong></p><p>Your doctor will decide how much Cosentyx you need and for how long.</p><p>&nbsp;</p><p><u>Plaque psoriasis</u></p><p><em><u>Adult</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 300&nbsp;mg by subcutaneous injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 300&nbsp;mg dose <strong>is given as one injection of 300&nbsp;mg</strong>.</p><p>&nbsp;</p><p>After the first dose you will receive further weekly injections at weeks&nbsp;1, 2, 3 and 4 followed by monthly injections. Based on your response, further adjustments to your dose may be recommended by your doctor. At each timepoint you will receive a 300&nbsp;mg dose given as one injection of 300&nbsp;mg.</p><p>&nbsp;</p><p><u>Children aged 6&nbsp;years and older</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is based on body weight as follows:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight below 25&nbsp;kg: 75&nbsp;mg by subcutaneous injection.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight 25&nbsp;kg or above and below 50&nbsp;kg: 75&nbsp;mg by subcutaneous injection.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight 50&nbsp;kg or above: 150&nbsp;mg by subcutaneous injection.</p><p>Your doctor may increase the dose to 300&nbsp;mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 300&nbsp;mg dose <strong>is given as one injection of 300&nbsp;mg or as two injections of 150&nbsp;mg</strong>. Other dosage forms/strengths may be available for administration of the 75&nbsp;mg and 150&nbsp;mg doses.</p><p>&nbsp;</p><p>After the first dose you will receive further weekly injections at weeks&nbsp;1, 2, 3 and 4 followed by monthly injections.</p><p>&nbsp;</p><p><u>Hidradenitis suppurativa</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 300&nbsp;mg by subcutaneous injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 300&nbsp;mg dose <strong>is given as one injection of 300&nbsp;mg.</strong></p><p>&nbsp;</p><p>After the first dose you will receive further weekly injections at weeks&nbsp;1, 2, 3 and 4 followed by monthly injections. Based on your response, further adjustments to your dose may be recommended by your doctor.</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p>If you have both psoriatic arthritis and also moderate to severe plaque psoriasis, your doctor may adjust</p><p>the dose recommendation as needed.</p><p>&nbsp;</p><p>For patients who did not respond well to medicines called tumour necrosis factor (TNF) blockers:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 300&nbsp;mg by subcutaneous injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 300&nbsp;mg dose <strong>is given as one injection of 300&nbsp;mg</strong>.</p><p>&nbsp;</p><p>After the first dose you will receive further weekly injections at weeks&nbsp;1, 2, 3 and 4 followed by monthly injections. At each timepoint you will receive a 300&nbsp;mg dose given as one injection of 300&nbsp;mg.</p><p><u>&nbsp;</u></p><p><u>For other psoriatic arthritis patients:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 150&nbsp;mg by subcutaneous injection. Other dosage forms/strengths are available for the 150&nbsp;mg dose.</p><p>&nbsp;</p><p>After the first dose you will receive further weekly injections at weeks&nbsp;1, 2, 3 and 4 followed by monthly injections.</p><p>&nbsp;</p><p>Based on your response, your doctor may increase your dose to 300&nbsp;mg.</p><p>&nbsp;</p><p><u>Ankylosing spondylitis (Radiographic axial spondyloarthritis)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 150&nbsp;mg by subcutaneous injection. Other dosage forms/strengths are available for the 150&nbsp;mg dose.</p><p>&nbsp;</p><p>After the first dose you will receive further weekly injections at weeks&nbsp;1, 2, 3 and 4 followed by monthly injections.</p><p>&nbsp;</p><p>Based on your response, your doctor may increase your dose to 300&nbsp;mg. Each 300&nbsp;mg dose is given as one injection of 300&nbsp;mg.</p><p>&nbsp;</p><p><u>Non-radiographic axial spondyloarthritis</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 150&nbsp;mg by subcutaneous injection. Other dosage forms/strengths are available for the 150&nbsp;mg dose.</p><p>&nbsp;</p><p>After the first dose you will receive further weekly injections at weeks&nbsp;1, 2, 3 and 4 followed by monthly injections.</p><p>&nbsp;</p><p>Cosentyx is for long‑term treatment. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.</p><p>&nbsp;</p><p><strong>If you use more Cosentyx than you should</strong></p><p>If you have received more Cosentyx than you should or the dose has been administered sooner than according to your doctor&rsquo;s prescription, inform your doctor.</p><p><em>&nbsp;</em></p><p><strong>If you forget to use Cosentyx</strong></p><p>If you have forgotten to inject a dose of Cosentyx, inject the next dose as soon as you remember. Then talk to your doctor to discuss when you should inject the next dose.</p><p>&nbsp;</p><p><strong>If you stop using Cosentyx</strong></p><p>It is not dangerous to stop using Cosentyx. However, if you stop, your psoriasis, psoriatic arthritis or axial spondyloarthritis symptoms may come back.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><u>Stop using Cosentyx and tell your doctor or seek medical help immediately</u> if you get any of the following side effects:</p><p>&nbsp;</p><p><strong>Possible serious infection</strong> - the signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, flu‑like symptoms, night sweats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired or short of breath, cough which will not go away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warm, red and painful skin, or a painful skin rash with blisters.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning sensation when passing urine.</p><p>&nbsp;</p><p><strong>Serious allergic reaction</strong> - the signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing or swallowing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, which can cause dizziness or light‑headedness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe itching of the skin, with a red rash or raised bumps.</p><p>Your doctor will decide if and when you may restart the treatment.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Most of the following side effects are mild to moderate. If any of these side effects becomes severe, tell your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infections with symptoms such as sore throat and stuffy nose (nasopharyngitis, rhinitis)</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cold sores (oral herpes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny nose (rhinorrhoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral thrush (oral candidiasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of low levels of white blood cells, such as fever, sore throat or mouth ulcers due to infections (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the external ear (otitis externa)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discharge from the eye with itching, redness and swelling (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower respiratory tract infections</p><p>abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; small, itchy blisters on the palms of hands, soles of feet and edges of the fingers and toes (dyshidrotic eczema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; athlete&rsquo;s foot (tinea pedis)</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1&nbsp;000&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction with shock (anaphylactic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness and shedding of skin over a larger area of the body, which may be itchy or painful (exfoliative dermatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of small blood vessels, which can lead to a skin rash with small red or purple bumps (vasculitis)</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections of the skin and mucous membranes (including oesophageal candidiasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful swelling and skin ulceration (pyoderma gangrenosum)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after the expiry date which is stated on the outer box or the label on the pen after &ldquo;EXP&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the liquid contains easily visible particles, is cloudy or is distinctly brown.</p><p>&nbsp;</p><p>Store the pen sealed in its box to protect from light. Store in the refrigerator between 2&deg;C and 8&deg;C. Do not freeze. Do not shake.</p><p>If necessary, Cosentyx can be left out of the refrigerator for a single period of up to 4&nbsp;days at room temperature, not above 30&deg;C.</p><p>&nbsp;</p><p>This medicine is for single use only.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is secukinumab. Each pre-filled pen contains 300&nbsp;mg secukinumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are trehalose dihydrate, histidine, histidine hydrochloride monohydrate, methionine, polysorbate 80 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cosentyx solution for injection is a clear liquid. Its colour may vary from colourless to slightly yellow.
Cosentyx 300 mg solution for injection in pre-filled pen is available in a pack containing 1 pre filled pen and in multipacks containing 3 (3 packs of 1) pre-filled pens.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2023
e. e.	To report any side effect(s):
•	Saudi Arabia

The National Pharmacovigilance Centre (NPC):

o Fax: +966-11-205-7662
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار كوسينتيكس على المادة الفعَّالة سيكوكينوماب. سيكوكينوماب هو أحد الأجسام المضادة أُحادِية النَّسِيْلَة التي تنتمي إلى مجموعة من الأدوية تسمى مثبطات الإنترلوكين. يعمل هذا الدَّواء عن طريق تحييد نشاط بروتين يُدعى إنترلوكين - 17أ، والذي يوجد بمستويات مرتفعة في حالة الإصابة بأمراض، مثل: الصَّدفية، التهاب الغدد العرقية القيحي، والتهاب المفاصل الصَّدفي، والتهاب المفاصل الفقاري المحوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار كوسينتيكس لعلاج الأمراض الالتهابية التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصَّدفية اللويحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدد العرقية القيحي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الصَّدفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الفقاري المحوري، بما في ذلك التهاب الفقار اللاصق (التهاب المفاصل الفقاري المحوري الذي يظهر في التصوير الإشعاعي) والتهاب المفاصل الفقاري المحوري الذي لا يظهر في التصوير الإشعاعي.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الصَّدفية اللويحية</strong></p><p dir="RTL">يُستَخدَم عقار كوسينتيكس لعلاج حالة جلدية تُدعى &quot;الصَّدفية اللويحية&quot;، والتي تسبب التهابًا يُؤثر على الجلد. يقلل عقار كوسينتيكس من الالتهاب والأعراض الأخرى للمرض. يُستَخدَم عقار كوسينتيكس في البالغين والمراهقين والأطفال (البالغين من العمر 6 أعوام وأكبر) الذين يعانون من صدفية لويحية معتدلة إلى شديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيفيدك استخدام عقار كوسينتيكس في حالة الإصابة بالصَّدفية اللويحية من خلال تحسين حالة الجلد، وتقليل الأعراض التي تعاني منها، مثل: التَّقشُّر، والحكة، والألم.</p><p dir="RTL"><strong>التهاب الغدد العرقية القيحي</strong></p><p dir="RTL">يُستَخدَم عقار كوسينتيكس لعلاج حالة تُدعى &quot;التهاب الغدد العرقية القيحي&quot;، وتُدعى في بعض الأحيان &quot;حب الشباب العكسي&quot; أو &quot;مرض فِيرنُوي&quot;. هذه الحالة عبارة عن مرض جلدي التهابي مزمن ومؤلم. قد تشمل الأعراض عقيدات (كتلًا) تؤلم عند لمسها وخراجات (دَمامِل) قد يتسرب منها القيح. وتؤثر بشكل شائع على مناطق معينة من الجلد، مثل: تحت الثديين، والإبطين، والسَّطحين الدَّاخليَّيْن من الفخذين، والأربية والأرداف. كما قد تظهر ندبات في المناطق المُصابة.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">سيُفيدك استخدام عقار كوسينتيكس في التهاب الغدد العرقية القيحي عن طريق تقليل عدد العقيدات والخراجات التي تعاني منها والألم الذي يصاحب هذا المرض غالبًا.إذا كنت مصابًا بالتهاب الغدد العرقية القيحي ، فسيتم إعطاؤك أولاً أدوية أخرى. إذا لم تستجيب بشكل جيد لهذه الأدوية ، فسوف يتم إعطاؤك عقار كوسينتيكس .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار كوسينتيكس في البالغين المصابين بالتهاب الغدد العرقية القيحي، ويُمكِن استخدامه بمفرده، أو مع مضادات حيوية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التهاب المفاصل الصَّدفي</strong></p><p dir="RTL">يُستَخدَم عقار كوسينتيكس لعلاج حالة تُدعى &quot;التهاب المفاصل الصَّدفي&quot;. تُعَد هذه الحالة مرضًا التهابيًّا بالمفاصل، وغالبًا ما يكون مصحوبًا بالإصابة بالصَّدفية. إذا كنت مُصابًا بالتهاب المفاصل الصَّدفي النَّشط، فسيتم إعطاؤك أدوية أخرى أولًا. إذا لم تستجب بشكلٍ جيد بما فيه الكفاية لهذه الأدوية، فسيتم إعطاؤك عقار كوسينتيكس؛ لتقليل علامات وأعراض التهاب المفاصل الصَّدفي النَّشط، وتحسين الوظائف البدنية، وإبطاء تلف غضاريف وعظام المفاصل المتأثرة بالمرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار كوسينتيكس في البالغين المصابين بالتهاب المفاصل الصَّدفي النَّشط، ويُمكِن استخدامه بمفرده، أو مع دواء آخر يُدعى ميثوتريكسات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيفيدك استخدام عقار كوسينتيكس في حالة الإصابة بالتهاب المفاصل الصَّدفي من خلال تقليل علامات المرض وأعراضه، وإبطاء تلف غضاريف وعظام المفاصل، وتحسين قدرتك على القيام بالأنشطة اليومية العادية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الفقاري المحوري، بما في ذلك التهاب الفقار اللاصق (التهاب المفاصل الفقاري المحوري الذي يظهر في التصوير الإشعاعي) والتهاب المفاصل الفقاري المحوري الذي لا يظهر في التصوير الإشعاعي</strong></p><p dir="RTL">يُستَخدَم عقار كوسينتيكس لعلاج حالات تُدعى &quot;التهاب الفقار اللاصق&quot; و&quot;التهاب المفاصل الفقاري المحوري الذي لا يظهر في التصوير الإشعاعي&quot;. تُعَد هذه الحالات أمراضًا التهابية تُصيب العمود الفقري بشكل رئيسي؛ مما يُسبب التهابًا بمفاصل العمود الفقري. إذا كنت مُصابًا بالتهاب الفقار اللاصق أو بالتهاب المفاصل الفقاري المحوري الذي لا يظهر في التصوير الإشعاعي، فسيتم إعطاؤك أدوية أخرى أولًا. إذا لم تستجب بشكلٍ جيد بما فيه الكفاية لهذه الأدوية، فسيتم إعطاؤك عقار كوسينتيكس؛ لتقليل علامات المرض وأعراضه، وتقليل الالتهاب، وتحسين وظائفك البدنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار كوسينتيكس في البالغين المصابين بالتهاب الفقار اللاصق النَّشط والتهاب المفاصل الفقاري المحوري النَّشط الذي لا يظهر في التصوير الإشعاعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيفيدك استخدام عقار كوسينتيكس في حالة الإصابة بالتهاب الفقار اللاصق والتهاب المفاصل الفقاري المحوري الذي لا يظهر في التصوير الإشعاعي من خلال تقليل علامات وأعراض المرض الذي تعاني منه، وتحسين وظائفك البدنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار كوسينتيكس في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من حساسية</strong> تجاه سيكوكينوماب أو تجاه أيٍّ من المكونات الأخرى الموجودة بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">إذا كنت تعتقد أنك قد تكون لديك حساسية، فاستشر طبيبك قبل استخدام عقار كوسينتيكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت مُصابًا بعدوى نشطة </strong>يرى طبيبك أنها ذات أهمية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الممرض(ة) أو الصيدلي الخاص بك قبل استخدام عقار كوسينتيكس في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بعدوى في الوقت الحالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بعدوى طويلة الأمد أو متكررة الحدوث.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمرض السُّل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمرض التهابي بالأمعاء يُدعى مرض كرون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بالتهاب في الأمعاء الغليظة لديك يُدعى التهاب القولون التقرحي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت لقاحًا مؤخرًا، أو إذا كان من المُقرر أن تتلقى لقاحًا أثناء العلاج بعقار كوسينتيكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أيَّ علاج آخر لمرض الصَّدفية، مثل: كابت آخر للمناعة، أو العلاج الضَّوئي بالأشعة فوق البنفسجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مرض الأمعاء الالتهابي (مرض كرون أو التهاب القولون التقرُّحي)</strong></p><p dir="RTL">توقف عن استخدام عقار كوسينتيكس، وأخبر طبيبك أو اطلب المساعدة الطبية فورًا إذا لاحظت إصابتك بتقلصات وألم في البطن، إِسْهال، فقدان الوزن أو وجود دم في البراز أو أي علامات أخرى تشير إلى وجود مشاكل بالأمعاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتبه إلى العدوى وتفاعلات الحساسية</strong></p><p dir="RTL">من المُمكِن أن يُسبب عقار كوسينتيكس أعراضًا<strong> </strong>جانبية خطيرة، بما في ذلك العدوى وتفاعلات الحساسية. عليك الانتباه إلى علامات هذه الحالات أثناء تلقيك لعقار كوسينتيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توقف عن استخدام عقار كوسينتيكس، وأخبر طبيبك أو اطلب المساعدة الطبية فورًا إذا لاحظت وجود أيِّ علامات تُشير إلى إصابتك بعدوى خطيرة مُحتَمَلة أو إحدى تفاعلات الحساسية. هذه العلامات مُدرَجة تحت عنوان &quot;الأعراض الجانبية الخطيرة&quot; في قسم: 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام عقار كوسينتيكس للأطفال الذين تقل أعمارهم عن 6 أعوام المصابين بالصَّدفية اللويحية؛ لأنَّه لم تتم دراسته في هذه الشريحة العُمْرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُوصى باستخدام عقار كوسينتيكس للأطفال والمراهقين (الذين تقل أعمارهم عن 18 عامًا) لدواعي الاستعمال الأخرى؛ لأنَّه لم تتم دراسته في هذه الشريحة العُمْرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام عقار كوسينتيكس مع أدوية أخرى</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك في الحالتين الآتيتين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت مؤخرًا أو كان من المُقرر أن تتلقى لقاحًا. يجب ألا تُعطى أنواعًا معينة من اللقاحات (اللقاحات الحية) أثناء استخدام عقار كوسينتيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">يُفضَّل تجنُّب استخدام عقار كوسينتيكس أثناء الحمل. تأثيرات هذا الدَّواء على السيدات الحوامل غير معروفة. إذا كنتِ سيدة لديكِ القدرة على الإنجاب، فيُنصَح بتجنُّب الحمل، وعليكِ استخدام وسيلة منع حمل مناسبة أثناء استخدام عقار كوسينتيكس ولمدة 20 أسبوعًا على الأقل بعد تلقي آخر جرعة من عقار كوسينتيكس.</p><p dir="RTL">تحدَّثي إلى طبيبكِ إذا كنتِ حاملًا أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدَّثي إلى طبيبكِ إذا كنتِ مُرضعًا أو تخططين للإرضاع. يجب أن تقرري أنتِ وطبيبكِ ما إذا كنتِ ستُمارسين الرَّضاعة الطبيعية، أم ستستخدمين عقار كوسينتيكس. حيث يجب أَلَّا تقومي بالأمرين معًا. بعد استخدام عقار كوسينتيكس يجب أَلَّا تمارسي الرَّضاعة الطبيعية لمدة 20 أسبوعًا على الأقل بعد تلقي آخر جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يُؤثر عقار كوسينتيكس على قدرتك على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك أو الممرض(ة) أو الصيدلي الخاص بك إذا لم تكن متأكدًا من طريقة الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطى عقار كوسينتيكس عن طريق الحَقْن أسفل الجلد لديك. يجب أن تقرر أنت وطبيبك ما إذا كان عليك حَقْن نفسك بعقار كوسينتيكس أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المُهِم أَلَّا تحاول حَقْن نفسك حتى يقوم طبيبك أو الممرض(ة) أو الصيدلي الخاص بك بتدريبك على القيام بذلك. بإمكان مقدم الرعاية كذلك أن يُعطيك حُقَن عقار كوسينتيكس الخاصة بك بعد تلقي التَّدريب المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للاطلاع على التَّعليمات المُفصَّلة حول طريقة حَقْن عقار كوسينتيكس، انظر: &quot;تعليمات استخدام قلم أونوريدي الخاص بعقار كوسينتيكس 300 مجم&quot; في نهاية هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما الكمية التي تُعطى من عقار كوسينتيكس؟ وكم تكون مدة إعطاء العقار؟</strong></p><p dir="RTL">سيقرر طبيبك الكمية التي تحتاج إليها من عقار كوسينتيكس، ومدة إعطائه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الصَّدفية اللويحية</u></p><p dir="RTL"><em><u>البالغون</u></em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها هي 300 مجم عن طريق الحقن أسفل الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُعطى كل جرعة قدرها 300 مجم على هيئة عملية حَقْن واحدة تبلغ 300 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي الجرعة الأولى، ستتلقى عمليات الحَقْن الأسبوعية اللاحقة في الأسبوع 1 و2 و3 و4 تليها عمليات الحَقْن الشهرية. بناءً على استجابتك ، قد يوصي طبيبك بإجراء مزيد من التعديلات على جرعتك. في كل نقطة زمنية ستتلقى جرعة قدرها 300 مجم تُعطى على هيئة عملية حَقْن واحدة قدرها 300 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال ممن تبلغ أعمارهم 6 أعوام فأكثر</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتمد الجرعة المُوصى بها على وزن الجسم على النحو الآتي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كان الوزن أقل من 25 كجم: 75 مجم عن طريق الحَقْن أسفل الجلد.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كان الوزن يبلغ 25 كجم أو أكثر وأقل من 50 كجم: 75 مجم عن طريق الحَقْن أسفل الجلد.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كان الوزن 50 كجم أو أكثر: 150 مجم عن طريق الحَقْن أسفل الجلد.</p><p dir="RTL">قد يقوم طبيبك بزيادة الجرعة إلى 300 مجم.</p><p dir="RTL">تُعطى كل جرعة قدرها 300 مجم على هيئة عملية حَقْن واحدة تبلغ 300 مجم أو على هيئة عمليتي حَقْن تبلغ كل منهما 150 مجم. قد تتوفر أشكال/ تركيزات أخرى للجرعة لإعطاء الجرعات التي تبلغ 75 مجم و150 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي الجرعة الأولى، ستتلقى عمليات الحَقْن الأسبوعية اللاحقة في الأسبوع 1 و2 و3 و4 تليها عمليات الحَقْن الشهرية.</p><p dir="RTL"><u>التهاب الغدد العرقية القيحي</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها هي 300 مجم عن طريق الحَقْن أسفل الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُعطى كل جرعة قدرها 300 مجم على هيئة عملية حَقْن واحدة تبلغ 300 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي الجرعة الأولى، ستتلقى عمليات الحَقْن الأسبوعية اللاحقة في الأسبوع 1 و2 و3 و4 تليها عمليات الحَقْن الشهرية. بناءً على استجابتك ، قد يوصي طبيبك بإجراء مزيد من التعديلات على جرعتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب المفاصل الصَّدفي</u></p><p dir="RTL">إذا كنت تعاني من التهاب المفاصل الصدفي وكذلك الصدفية اللويحية المعتدلة إلى الشديدة ، فقد يقوم طبيبك بتعديل الجرعة الموصى بها حسب الحاجة.</p><p dir="RTL">بالنسبة للمرضى الذين لم يستجيبوا جيدًا للأدوية التي تُدعى حاصرات عامل نخر الورم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها هي 300 مجم عن طريق الحقن أسفل الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُعطى كل جرعة قدرها 300 مجم على هيئة عملية حَقْن واحدة تبلغ 300 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي الجرعة الأولى، ستتلقى عمليات الحَقْن الأسبوعية اللاحقة في الأسبوع 1 و2 و3 و4 تليها عمليات الحَقْن الشهرية. في كل نقطة زمنية ستتلقى جرعة قدرها 300 مجم تُعطى على هيئة عملية حَقْن واحدة تبلغ 300 مجم.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>بالنِّسبة لمرضى التهاب المفاصل الصَّدفي الآخرين:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها هي 150 مجم عن طريق الحَقْن أسفل الجلد. تتوفر أشكال / تراكيز أخرى لجرعة 150 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي الجرعة الأولى، ستتلقى عمليات الحَقْن الأسبوعية اللاحقة في الأسبوع 1 و2 و3 و4 تليها عمليات الحَقْن الشهرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بناءً على استجابتك، قد يقوم طبيبك بزيادة جرعتك إلى 300 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب الفقار اللاصق (التهاب المفاصل الفقاري المحوري الذي يظهر في التصوير الإشعاعي)</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها هي 150 مجم عن طريق الحَقْن أسفل الجلد. تتوفر أشكال / تراكيز أخرى لجرعة 150 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي الجرعة الأولى، ستتلقى عمليات الحَقْن الأسبوعية اللاحقة في الأسبوع 1 و2 و3 و4 تليها عمليات الحَقْن الشهرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بناءً على استجابتك، قد يقوم طبيبك بزيادة جرعتك إلى 300 مجم. تُعطى كل جرعة قدرها 300 مجم على هيئة عملية حَقْن واحدة قدرها 300 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب المفاصل الفقاري المحوري الذي لا يظهر في التصوير الإشعاعي</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها هي 150 مجم عن طريق الحَقْن أسفل الجلد. تتوفر أشكال / تراكيز أخرى لجرعة 150 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي الجرعة الأولى، ستتلقى عمليات الحَقْن الأسبوعية اللاحقة في الأسبوع 1 و2 و3 و4 تليها عمليات الحَقْن الشهرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار كوسينتيكس مُعدٌّ للعلاج طويل الأمد. سيراقب طبيبك حالتك بصفة منتظمة؛ ليتأكد من أنَّ العلاج يحقق التَّأثير المرجو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت كمية أكثر مما يجب من عقار كوسينتيكس</strong></p><p dir="RTL">إذا تلقيت كمية أكثر مما يجب من عقار كوسينتيكس أو تم إعطاؤك الجرعة في وقت أقرب من الذي وصفه لك طبيبك، فأبلِغ طبيبك.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>إذا أغفلت استخدام عقار كوسينتيكس</strong></p><p dir="RTL">إذا أغفلت حَقْن جرعةٍ من عقار كوسينتيكس، فقم بحَقْن الجرعة التَّالية بمجرد تذكُّرك. ثم تحدَّث إلى طبيبك لمناقشة متى يجب عليك حَقْن الجرعة التَّالية.</p><p dir="RTL"><strong>إذا توقفت عن استخدام عقار كوسينتيكس</strong></p><p dir="RTL">التَّوقف عن استخدام عقار كوسينتيكس ليس أمرًا خطيرًا. مع ذلك، إذا توقفت عن استخدامه، فقد تعود أعراض الصَّدفية أو التهاب المفاصل الصَّدفي أو التهاب المفاصل الفقاري المحوري مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أعراضًا جانبية على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL"><u>توقف عن استخدام عقار كوسينتيكس، وأخبِر طبيبك أو اطلب المساعدة الطبية فورًا</u> إذا تعرَّضت لأيٍّ من الأعراض الجانبية التَّالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإصابة بعدوى خطيرة مُحتمَلة </strong>- قد تشمل العلامات ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى، أعراضًا شبيهة بالإنفلونزا، تعرُّقًا ليليًّا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعورًا بالتَّعب أو ضيقًا بالتَّنفس، سُعالًا لا يزول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلدًا دافئًا ومؤلمًا وبه احمرار، أو طفحًا جلديًّا مؤلمًا مصحوبًا ببثور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساسًا بالحُرقة عند التبوُّل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإصابة بتفاعل حساسية خطير</strong> - قد تشمل العلامات ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التَّنفس أو البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم؛ مما قد يُسبب دوخة أو دوارًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الوجه، أو الشفتين، أو اللسان، أو الحَلْق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكَّة شديدة بالجلد مصحوبة بطفح جلدي أحمر اللون أو نتوءات بارزة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك ما إذا كان بإمكانك استئناف العلاج أم لا، ومتى سيتم ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">تُعد غالبية الأعراض<strong> </strong>الجانبية التَّالية خفيفة إلى مُعتَدلة. إذا أصبح أيٌّ من هذه الأعراض<strong> </strong>الجانبية شديدًا، فأخبِر طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من شخص واحد من بين كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالجهاز التَّنفسي العلوي مصحوبة بأعراض، مثل: التهاب الحَلْق وانسداد الأنف (التهاب البلعوم الأنفي، التهاب الأنف).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح البرد (الهربس الفموي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق.</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُلَاق فموي (داء المبيضات الفموي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات انخفاض مستويات خلايا الدَّم البيضاء، مثل: الحُمى، أو التهاب الحَلْق، أو قرح الفم بسبب العدوى (قلة خلايا العَدِلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالأذن الخارجية (التهاب الأذن الخارجية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفرازات من العين مصحوبة بحكة، واحمرار، وتورُّم (التهاب الملتحمة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب بحكة (أرتكاريا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالجهاز التنفسي السفلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات وألم في البطن، إِسْهال، فقدان الوزن أو وجود دم في البراز (علامات تشير إلى وجود مشاكل في الأمعاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور صغيرة مثيرة للحكة على راحتي اليدين وباطن القدمين وحواف أصابع اليدين والقدمين (إكزيما خلل التعرق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القدم الرياضي (سَعْفَة القَدَم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد مصحوب بصدمة (تفاعل تَأَقيّ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار وتقشُّر الجلد على مساحة كبيرة من الجسم، وهو ما قد يكون مصحوبًا بحكة أو ألم (التهاب الجلد التقشُّري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية الصغيرة؛ الأمر الذي قد يؤدي إلى الإصابة بطفح جلدي مصحوب بنتوءات صغيرة حمراء أو أرجوانية اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يُمكن تقدير مُعدَّل التكرار من واقع البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية بالجلد والأغشية المخاطية (بما في ذلك داء المبيضات بالمريء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم مؤلم و تقيح جلدي (تقيح الجلد الغنغريني).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الابلاغ عن الأثار الجانبية: </strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية ، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية ، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد انتهاء تاريخ الصَّلاحية المدوَّن على العبوة الخارجية أو المُلصَق الموجود على القلم بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان السائل يحتوي على جسيمات يسهل رؤيتها، أو كان غائمًا، أو كان لونه بنيًّا بشكل واضح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ القلم مغلقًا بإحكام في عبوته لحمايته من الضوء. يُحفَظ في الثَّلاجة في درجة حرارة تتراوح بين 2 - 8 درجات مئوية. لا تعرضه للتَّجميد. لا تقم بِرجِّه.</p><p dir="RTL">إذا لزم الأمر، يمكن ترك عقار كوسينتيكس خارج الثلاجة لفترة واحدة تصل إلى 4 أيام في درجة حرارة الغرفة، ولا تتعدى 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الدَّواء مُعدٌّ للاستخدام مرة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق إلقائها في مياه الصَّرف. استشِر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي سيكوكينوماب. يحتوي كل قلم معبأ مسبقًا على 300 مجم من سيكوكينوماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: طرهالوز ثنائي الهيدرات، هيستيدين، هيستيدين هيدروكلوريد أحادي الهيدرات، ميثيونين، بوليسوربات 80 وماء للحَقْن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار كوسينتيكس محلول للحَقْن هو عبارة عن سائل صافٍ. قد يتباين لونه بين عديم اللون إلى المائل إلى الأصفر.</p><p dir="RTL">يتوفر عقار كوسينتيكس 300 مجم محلول للحقن في أقلام معبأة مسبقًا في عبوة تحتوي على قلم واحد معبأ مسبقًا، وفي عبوات متعددة تحتوي على 3 أقلام معبأة مسبقًا (3 عبوات بكل منها قلم واحد).</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2023
هـ. للإبلاغ عن الأعراض الجانبية : 

المملكة العربية السعودية
  - المركز الوطني للتيقظ والسلامة الدوائية (NPC)
•	الفاكس: +966-11-205-7662
•	مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
•	البريد الالكتروني: npc.drug@sfda.gov.sa
•	الموقع الالكتروني: https://ade.sfda.gov.sa

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
•	الهاتف المجاني: 8001240078
•	الهاتف:  +966112658100
•	الفاكس: +966112658107
•	البريد الالكتروني: adverse.events@novartis.com

دول مجلس التَّعاون الخليجي الأخرى: 
- يُرجى الاتصال بسلطات الاختصاص المعنية


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cosentyx 150 mg solution for injection in pre-filled syringe
Cosentyx 300 mg solution for injection in pre-filled syringe
Cosentyx 150 mg solution for injection in pre-filled pen
Cosentyx 300 mg solution for injection in pre-filled pen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cosentyx 150 mg solution for injection in pre-filled syringe

Each pre filled syringe contains 150 mg secukinumab in 1 ml.

Cosentyx 300 mg solution for injection in pre-filled syringe

Each pre filled syringe contains 300 mg secukinumab in 2 ml.

Cosentyx 150 mg solution for injection in pre-filled pen

Each pre filled pen contains 150 mg secukinumab in 1 ml.

Cosentyx 300 mg solution for injection in pre-filled pen

Each pre filled pen contains 300 mg secukinumab in 2 ml.

Secukinumab is a recombinant fully human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

The solution is clear and colourless to slightly yellow.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adult p</u><u>laque psoriasis</u></p><p>&nbsp;</p><p>Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.</p><p>&nbsp;</p><p><u>Paediatric plaque psoriasis</u></p><p>&nbsp;</p><p>Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6&nbsp;years who are candidates for systemic therapy.</p><p><u>Hidradenitis suppurativa (HS)</u></p><p>&nbsp;</p><p>Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p>&nbsp;</p><p>Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease‑modifying anti‑rheumatic drug (DMARD) therapy has been inadequate (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Axial spondyloarthritis (axSpA)</u></p><p><u>&nbsp;</u></p><p><em><u>Ankylosing spondylitis</u></em><u> <em>(AS, radiographic axial spondyloarthritis)</em></u></p><p>Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.</p><p>&nbsp;</p><p><em><u>Non-radiographic axial spondyloarthritis (nr-axSpA)</u></em></p><p>Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non‑steroidal anti‑inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p><u>Juvenile idiopathic arthritis (JIA)</u></p><p><u>&nbsp;</u></p><p><em><u>Enthesitis-related arthritis (ERA)</u></em></p><p>Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6&nbsp;years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy (see section&nbsp;5.1).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Juvenile psoriatic arthritis (JPsA)</u></em></p><p>Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6&nbsp;years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Adult plaque psoriasis</u></em></p><p>The recommended dose is 300&nbsp;mg of secukinumab by subcutaneous injection with initial dosing at weeks&nbsp;0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, a maintenance dose of 300&nbsp;mg every 2&nbsp;weeks may provide additional benefit for patients with a body weight of 90&nbsp;kg or higher. Each 300&nbsp;mg dose is given as one subcutaneous injection of 300&nbsp;mg or as two subcutaneous injections of 150&nbsp;mg.</p><p>&nbsp;</p><p><u>Paediatric plaque psoriasis (adolescents and children from the age of 6&nbsp;years)</u></p><p>The recommended dose is based on body weight (Table&nbsp;1) and administered by subcutaneous injection with initial dosing at weeks&nbsp;0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 75&nbsp;mg dose is given as one subcutaneous injection of 75&nbsp;mg. Each 150&nbsp;mg dose is given as one subcutaneous injection of 150&nbsp;mg. Each 300&nbsp;mg dose is given as one subcutaneous injection of 300&nbsp;mg or as two subcutaneous injections of 150&nbsp;mg.</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose for paediatric plaque psoriasis</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:534px"><tbody><tr><td><p><strong>Body weight at time of dosing</strong></p></td><td><p><strong>Recommended dose</strong></p></td></tr><tr><td><p>&lt;25&nbsp;kg</p></td><td><p>75&nbsp;mg</p></td></tr><tr><td><p>25 to &lt;50&nbsp;kg</p></td><td><p>75&nbsp;mg</p></td></tr><tr><td><p>&ge;50&nbsp;kg</p></td><td><p>150&nbsp;mg (*may be increased to 300&nbsp;mg)</p></td></tr></tbody></table><p>*Some patients may derive additional benefit from the higher dose.</p><p>&nbsp;</p><p>The 150&nbsp;mg and 300&nbsp;mg solution for injection in pre-filled syringe and in pre-filled pen are not indicated for administration to paediatric patients with a weight &lt;50&nbsp;kg. Cosentyx may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em><u>Hidradenitis suppurativa (HS)</u></em></p><p>The recommended dose is 300&nbsp;mg of secukinumab by subcutaneous injection with initial dosing at weeks&nbsp;0, 1, 2, 3, and 4, followed by monthly maintenance dosing. Based on clinical response, the maintenance dose can be increased to 300&nbsp;mg every 2&nbsp;weeks. Each 300&nbsp;mg dose is given as one subcutaneous injection of 300&nbsp;mg or as two subcutaneous injections of 150&nbsp;mg.</p><p>&nbsp;</p><p><em><u>Psoriatic arthritis</u></em></p><p>For patients with concomitant moderate to severe plaque psoriasis, please refer to adult plaque psoriasis recommendation.</p><p>&nbsp;</p><p>For patients who are anti‑TNF&alpha; inadequate responders (IR), the recommended dose is 300&nbsp;mg by subcutaneous injection with initial dosing at weeks&nbsp;0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300&nbsp;mg dose is given as one subcutaneous injection of 300&nbsp;mg or as two subcutaneous injections of 150&nbsp;mg.</p><p>&nbsp;</p><p>For other patients, the recommended dose is 150&nbsp;mg by subcutaneous injection with initial dosing at weeks&nbsp;0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300&nbsp;mg.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Axial spondyloarthritis (axSpA)</u></em></p><p><em>Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)</em></p><p>The recommended dose is 150&nbsp;mg by subcutaneous injection with initial dosing at weeks&nbsp;0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300&nbsp;mg. Each 300&nbsp;mg dose is given as one subcutaneous injection of 300&nbsp;mg or as two subcutaneous injections of 150&nbsp;mg.</p><p>&nbsp;</p><p><em>Non-radiographic axial spondyloarthritis (nr-axSpA)</em></p><p>The recommended dose is 150&nbsp;mg by subcutaneous injection with initial dosing at weeks&nbsp;0, 1, 2, 3 and 4, followed by monthly maintenance dosing.</p><p><em><u>Juvenile idiopathic arthritis (JIA)</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA)</em></p><p>The recommended dose is based on body weight (Table&nbsp;2) and administered by subcutaneous injection at weeks&nbsp;0, 1, 2, 3, and 4, followed by monthly maintenance dosing. Each 75&nbsp;mg dose is given as one subcutaneous injection of 75&nbsp;mg. Each 150&nbsp;mg dose is given as one subcutaneous injection of 150&nbsp;mg.</p><p>&nbsp;</p><p><strong>Table&nbsp;2 Recommended dose for juvenile idiopathic arthritis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body weight at time of dosing</strong></p></td><td style="vertical-align:top"><p><strong>Recommended dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;50&nbsp;kg</p></td><td style="vertical-align:top"><p>75&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>&ge;50&nbsp;kg</p></td><td style="vertical-align:top"><p>150&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p>The 150&nbsp;mg and 300&nbsp;mg solution for injection in pre-filled syringe and in pre-filled pen are not indicated for administration to paediatric patients with a weight &lt;50&nbsp;kg. Cosentyx may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p>For all of the above indications, available data suggest that a clinical response is usually achieved within 16&nbsp;weeks of treatment. Consideration should be given to discontinuing treatment in patients who have shown no response by 16&nbsp;weeks of treatment. Some patients with an initial partial response may subsequently improve with continued treatment beyond 16&nbsp;weeks.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly patients (aged 65&nbsp;years and over)</u></em></p><p>No dose adjustment is required (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment / hepatic impairment</u></em></p><p>Cosentyx has not been studied in these patient populations. No dose recommendations can be made.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of Cosentyx in children with plaque psoriasis and in the juvenile idiopathic arthritis (JIA) categories of ERA and JPsA below the age of 6&nbsp;years have not been established.</p><p>&nbsp;</p><p>The safety and efficacy of Cosentyx in children below the age of 18&nbsp;years in other indications have not yet been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Cosentyx is to be administered by subcutaneous injection. If possible, areas of the skin that show psoriasis should be avoided as injection sites. The syringe or the pen must not be shaken.</p><p>&nbsp;</p><p>After proper training in subcutaneous injection technique, patients may self‑inject Cosentyx or be injected by a caregiver if a physician determines that this is appropriate. However, the physician should ensure appropriate follow‑up of patients. Patients or caregivers should be instructed to inject the full amount of Cosentyx according to the instructions provided in the package leaflet. Comprehensive instructions for administration are given in the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Clinically important, active infection, e.g. active tuberculosis (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p>Secukinumab has the potential to increase the risk of infections. Serious infections have been observed in patients receiving secukinumab in the post-marketing setting. Caution should be exercised when considering the use of secukinumab in patients with a chronic infection or a history of recurrent infection.</p><p>&nbsp;</p><p>Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and secukinumab should not be administered until the infection resolves.</p><p>&nbsp;</p><p>In clinical studies, infections have been observed in patients receiving secukinumab (see section&nbsp;4.8). Most of these were mild or moderate upper respiratory tract infections such as nasopharyngitis and did not require treatment discontinuation.</p><p>&nbsp;</p><p>Related to the mechanism of action of secukinumab, non‑serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies (3.55 per 100&nbsp;patient years for secukinumab 300&nbsp;mg versus 1.00 per 100&nbsp;patient years for placebo) (see section&nbsp;4.8).</p><p>&nbsp;</p><p>No increased susceptibility to tuberculosis was reported from clinical studies. However, secukinumab should not be given to patients with active tuberculosis. Anti‑tuberculosis therapy should be considered prior to initiation of secukinumab in patients with latent tuberculosis.</p><p>&nbsp;</p><p><u>Inflammatory bowel disease (including Crohn&rsquo;s disease and ulcerative colitis)</u></p><p>&nbsp;</p><p>Cases of new or exacerbations of inflammatory bowel disease have been reported with secukinumab (see section&nbsp;4.8). Secukinumab is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, secukinumab should be discontinued and appropriate medical management should be initiated.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>In clinical studies, rare cases of anaphylactic reactions have been observed in patients receiving secukinumab. If an anaphylactic or other serious allergic reactions occur, administration of secukinumab should be discontinued immediately and appropriate therapy initiated.</p><p>&nbsp;</p><p><u>Latex‑sensitive individuals &ndash; Cosentyx 150&nbsp;mg solution for injection in pre-filled syringe and 150&nbsp;mg solution for injection in pre-filled pen only</u></p><p>&nbsp;</p><p>The removable needle cap of Cosentyx 150&nbsp;mg solution for injection in pre‑filled syringe and Cosentyx</p><p>150&nbsp;mg solution for injection in pre-filled pen contains a derivative of natural rubber latex. No natural rubber latex has to date been detected in the removable needle cap. Nevertheless, the use of Cosentyx 150&nbsp;mg solution for injection in pre‑filled syringe and Cosentyx 150&nbsp;mg solution for injection in pre-filled pen in latex‑sensitive individuals has not been studied and there is therefore a potential risk of hypersensitivity reactions which cannot be completely ruled out.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>&nbsp;</p><p>Live vaccines should not be given concurrently with secukinumab.</p><p>&nbsp;</p><p>Patients receiving secukinumab may receive concurrent inactivated or non‑live vaccinations. In a study, after <em>meningococcal</em> and inactivated <em>influenza</em> vaccinations, a similar proportion of healthy volunteers treated with 150&nbsp;mg of secukinumab and those treated with placebo were able to mount an adequate immune response of at least a 4‑fold increase in antibody titres to<em> meningococcal</em> and <em>influenza</em> vaccines. The data suggest that secukinumab does not suppress the humoral immune response to the <em>meningococcal</em> or <em>influenza </em>vaccines.</p><p>&nbsp;</p><p>Prior to initiating therapy with Cosentyx, it is recommended that paediatric patients receive all age‑appropriate immunisations as per current immunisation guidelines.</p><p>&nbsp;</p><p><u>Concomitant immunosuppressive therapy</u></p><p>&nbsp;</p><p>In psoriasis studies, the safety and efficacy of secukinumab in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated. Secukinumab was administered concomitantly with methotrexate (MTX), sulfasalazine and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and ankylosing spondylitis). Caution should be exercised when considering concomitant use of other immunosuppressants and secukinumab (see also section&nbsp;4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Live vaccines should not be given concurrently with secukinumab (see also section&nbsp;4.4).</p><p>&nbsp;</p><p>In a study in adult subjects with plaque psoriasis, no interaction was observed between secukinumab and midazolam (CYP3A4 substrate).</p><p>&nbsp;</p><p>No interaction was seen when secukinumab was administered concomitantly with methotrexate (MTX) and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and axial spondyloarthritis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential should use an effective method of contraception during treatment and for at least 20&nbsp;weeks after treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of secukinumab in pregnant women.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see&nbsp; section&nbsp;5.3). As a precautionary measure, it is preferable to avoid the use of Cosentyx during pregnancy.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is not known whether secukinumab is excreted in human milk. Immunoglobulins are excreted in human milk and it is not known if secukinumab is absorbed systemically after ingestion. Because of the potential for adverse reactions in nursing infants from secukinumab, a decision on whether to discontinue breast‑feeding during treatment and up to 20&nbsp;weeks after treatment or to discontinue therapy with Cosentyx must be made taking into account the benefit of breast‑feeding to the child and the benefit of therapy to the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effect of secukinumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cosentyx has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions from clinical studies and post-marketing reports (Table&nbsp;3) are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1&nbsp;000 to &lt;1/100); rare (&ge;1/10&nbsp;000 to &lt;1/1&nbsp;000); very rare (&lt;1/10&nbsp;000); and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Over 20&nbsp;000&nbsp;patients have been treated with secukinumab in blinded and open‑label clinical studies in various indications (plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa and other autoimmune conditions), representing 34&nbsp;908&nbsp;patient years of exposure. Of these, over 14&nbsp;000&nbsp;patients were exposed to secukinumab for at least one year. The safety profile of secukinumab is consistent across all indications.</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of adverse reactions in clinical studies<sup>1)</sup> and post-marketing experience</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Upper respiratory tract infections</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oral herpes</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oral candidiasis</p></td></tr><tr><td style="vertical-align:top"><p>Otitis externa</p></td></tr><tr><td style="vertical-align:top"><p>Lower respiratory tract infections</p></td></tr><tr><td style="vertical-align:top"><p>Tinea pedis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Mucosal and cutaneous candidiasis (including oesophageal candidiasis)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rhinorrhoea</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Inflammatory bowel disease</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Dyshidrotic eczema</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis<sup>2)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity vasculitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pyoderma gangrenosum</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1)</sup> Placebo-controlled clinical studies (phase III) in plaque psoriasis, PsA, AS, nr-axSpA and HS patients exposed to 300&nbsp;mg, 150&nbsp;mg, 75&nbsp;mg or placebo up to 12&nbsp;weeks (psoriasis) or 16&nbsp;weeks (PsA, AS, nr-axSpA and HS) treatment duration</p><p><sup>2)</sup> Cases were reported in patients with psoriasis diagnosis</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Infections</u></em></p><p>In the placebo‑controlled period of clinical studies in plaque psoriasis (a total of 1&nbsp;382&nbsp;patients treated with secukinumab and 694&nbsp;patients treated with placebo for up to 12&nbsp;weeks), infections were reported in 28.7% of patients treated with secukinumab compared with 18.9% of patients treated with placebo. The majority of infections consisted of non‑serious and mild to moderate upper respiratory tract infections, such as nasopharyngitis, which did not necessitate treatment discontinuation. There was an increase in mucosal or cutaneous candidiasis, consistent with the mechanism of action, but the cases were mild or moderate in severity, non‑serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections occurred in 0.14% of patients treated with secukinumab and in 0.3% of patients treated with placebo (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Over the entire treatment period (a total of 3&nbsp;430&nbsp;patients treated with secukinumab for up to 52&nbsp;weeks for the majority of patients), infections were reported in 47.5% of patients treated with secukinumab (0.9 per patient‑year of follow‑up). Serious infections were reported in 1.2% of patients treated with secukinumab (0.015 per patient‑year of follow‑up).</p><p>&nbsp;</p><p>Infection rates observed in psoriatic arthritis and axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) clinical studies were similar to those observed in the psoriasis studies.</p><p>&nbsp;</p><p>Patients with hidradenitis suppurativa are more susceptible to infections. In the placebo‑controlled period of clinical studies in hidradenitis suppurativa (a total of 721&nbsp;patients treated with secukinumab and 363&nbsp;patients treated with placebo for up to 16&nbsp;weeks), infections were numerically higher compared to those observed in the psoriasis studies (30.7% of patients treated with secukinumab compared with 31.7% in patients treated with placebo). Most of these were non‑serious, mild or moderate in severity and did not require treatment discontinuation or interruption.</p><p>&nbsp;</p><p><em><u>Neutropenia</u></em></p><p>In psoriasis phase&nbsp;III clinical studies, neutropenia was more frequently observed with secukinumab than with placebo, but most cases were mild, transient and reversible. Neutropenia &lt;1.0‑0.5x10<sup>9</sup>/l (CTCAE grade&nbsp;3) was reported in 18 out of 3&nbsp;430&nbsp;(0.5%)&nbsp;patients on secukinumab, with no dose dependence and no temporal relationship to infections in 15 out of 18&nbsp;cases. There were no reported cases of more severe neutropenia. Non‑serious infections with usual response to standard care and not requiring discontinuation of secukinumab were reported in the remaining 3&nbsp;cases.</p><p>&nbsp;</p><p>The frequency of neutropenia in psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and hidradenitis suppurativa was similar to psoriasis.</p><p>&nbsp;</p><p>Rare cases of neutropenia &lt;0.5x10<sup>9</sup>/l (CTCAE grade&nbsp;4) were reported.</p><p>&nbsp;</p><p><em><u>Hypersensitivity reactions</u></em></p><p>In clinical studies, urticaria and rare cases of anaphylactic reaction to secukinumab were observed (see also section&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>In psoriasis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and hidradenitis suppurativa clinical studies, less than 1% of patients treated with secukinumab developed antibodies to secukinumab up to 52&nbsp;weeks of treatment. About half of the treatment‑emergent anti‑drug antibodies were neutralising, but this was not associated with loss of efficacy or pharmacokinetic abnormalities.</p><p><em>&nbsp;</em></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p><u>Undesirable effects in paediatric patients from the age of 6&nbsp;years with plaque psoriasis</u></p><p>The safety of secukinumab was assessed in two phase&nbsp;III studies in paediatric patients with plaque psoriasis. The first study (paediatric study&nbsp;1) was a double-blind, placebo-controlled study of 162&nbsp;patients from 6 to less than 18&nbsp;years of age with severe plaque psoriasis. The second study (paediatric study&nbsp;2) is an open-label study of 84&nbsp;patients from 6 to less than 18&nbsp;years of age with moderate to severe plaque psoriasis. The safety profile reported in these two studies was consistent with the safety profile reported in adult plaque psoriasis patients.</p><p><u>Undesirable effects in paediatric patients with JIA</u></p><p>The safety of secukinumab was also assessed in a phase&nbsp;III study in 86 juvenile idiopathic arthritis patients with ERA and JPsA from 2 to less than 18&nbsp;years of age. The safety profile reported in this study was consistent with the safety profile reported in adult patients.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o Fax: +966-11-205-7662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Doses up to 30&nbsp;mg/kg (approximately 2000 to 3000&nbsp;mg) have been administered intravenously in clinical studies without dose‑limiting toxicity. In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC10</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Secukinumab is a fully human IgG1/&kappa; monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin‑17A (IL‑17A). Secukinumab works by targeting IL‑17A and inhibiting its interaction with the IL‑17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL‑17A‑mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment with secukinumab reduces erythema,</p><p>induration and desquamation present in plaque psoriasis lesions.</p><p>&nbsp;</p><p>IL‑17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL‑17A plays a key role in the pathogenesis of plaque psoriasis, hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and is up‑regulated in lesional skin in contrast to non‑lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. IL‑17A is also upregulated in hidradenitis suppurativa lesions and increased IL‑17A serum levels have been observed in affected patients. The frequency of IL‑17‑producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis. Increased numbers of IL-17A producing lymphocytes have also been found in patients with non-radiographic axial spondyloarthritis. Inhibition of IL-17A was shown to be effective in the treatment of ankylosing spondylitis, thus establishing the key role of this cytokine in axial spondyloarthritis.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Serum levels of total IL17A (free and secukinumab-bound IL-17A) are initially increased in patients receiving secukinumab. This is followed by a slow decrease due to reduced clearance of secukinumab- bound IL-17A, indicating that secukinumab selectively captures free IL-17A, which plays a key role in the pathogenesis of plaque psoriasis.</p><p>&nbsp;</p><p>In a study with secukinumab, infiltrating epidermal neutrophils and various neutrophil‑associated markers that are increased in lesional skin of plaque psoriasis patients were significantly reduced after one to two weeks of treatment.</p><p>&nbsp;</p><p>Secukinumab has been shown to lower (within 1 to 2&nbsp;weeks of treatment) levels of C‑reactive protein, which is a marker of inflammation.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Adult plaque psoriasis</u></em></p><p>The safety and efficacy of secukinumab were assessed in four randomised, double‑blind, placebo‑controlled phase III studies in patients with moderate to severe plaque psoriasis who were candidates for phototherapy or systemic therapy [ERASURE, FIXTURE, FEATURE, JUNCTURE]. The efficacy and safety of secukinumab 150&nbsp;mg and 300&nbsp;mg were evaluated versus either placebo or etanercept. In addition, one study assessed a chronic treatment regimen versus a &ldquo;retreatment as needed&rdquo; regimen [SCULPTURE].</p><p>&nbsp;</p><p>Of the 2403&nbsp;patients who were included in the placebo‑controlled studies, 79% were biologic‑naive, 45% were non‑biologic failures and 8% were biologic failures (6% were anti‑TNF failures, and 2% were anti‑p40 failures). Approximately 15 to 25% of patients in phase III studies had psoriatic arthritis (PsA) at baseline.</p><p>&nbsp;</p><p>Psoriasis study&nbsp;1 (ERASURE) evaluated 738&nbsp;patients. Patients randomised to secukinumab received 150&nbsp;mg or 300&nbsp;mg doses at weeks&nbsp;0, 1, 2, 3 and 4, followed by the same dose every month. Psoriasis study&nbsp;2 (FIXTURE) evaluated 1&nbsp;306&nbsp;patients. Patients randomised to secukinumab received 150&nbsp;mg or 300&nbsp;mg doses at weeks&nbsp;0, 1, 2, 3 and 4, followed by the same dose every month. Patients randomised to etanercept received 50&nbsp;mg doses twice per week for 12&nbsp;weeks followed by 50&nbsp;mg every week. In both study&nbsp;1 and study&nbsp;2, patients randomised to receive placebo who were non‑responders at week&nbsp;12 then crossed over to receive secukinumab (either 150&nbsp;mg or 300&nbsp;mg) at weeks&nbsp;12, 13, 14, and 15, followed by the same dose every month starting at week&nbsp;16. All patients were followed for up to 52&nbsp;weeks following</p><p>first administration of study treatment.</p><p>&nbsp;</p><p>Psoriasis study&nbsp;3 (FEATURE) evaluated 177&nbsp;patients using a pre‑filled syringe compared with placebo after 12&nbsp;weeks of treatment to assess the safety, tolerability, and usability of secukinumab self‑administration via the pre‑filled syringe. Psoriasis study&nbsp;4 (JUNCTURE) evaluated 182&nbsp;patients using a pre‑filled pen compared with placebo after 12&nbsp;weeks of treatment to assess the safety, tolerability, and usability of secukinumab self‑administration via the pre‑filled pen. In both study&nbsp;3 and study&nbsp;4, patients randomised to secukinumab received 150&nbsp;mg or 300&nbsp;mg doses at weeks&nbsp;0, 1, 2, 3 and 4, followed by the same dose every month. Patients were also randomised to receive placebo at weeks&nbsp;0, 1, 2, 3 and 4, followed by the same dose every month.</p><p>&nbsp;</p><p>Psoriasis study&nbsp;5 (SCULPTURE) evaluated 966&nbsp;patients. All patients received secukinumab 150&nbsp;mg or 300&nbsp;mg doses at weeks&nbsp;0, 1, 2, 3, 4, 8 and 12 and then were randomised to receive either a maintenance regimen of the same dose every month starting at week&nbsp;12 or a &ldquo;retreatment as needed&rdquo; regimen of the same dose. Patients randomised to &ldquo;retreatment as needed&rdquo; did not achieve adequate maintenance of response and therefore a fixed monthly maintenance regimen is recommended.</p><p>&nbsp;</p><p>The co‑primary endpoints in the placebo and active‑controlled studies were the proportion of patients who achieved a PASI 75 response and IGA mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; response versus placebo at week&nbsp;12 (see Tables&nbsp;4 and 5). The 300&nbsp;mg dose provided improved skin clearance particularly for &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; skin across the efficacy endpoints of PASI 90, PASI 100, and IGA mod 2011 0 or 1 response across all studies with peak effects seen at week&nbsp;16, therefore this dose is recommended.</p><p><strong>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of PASI 50/75/90/100 &amp; IGA⃰ mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; clinical response in psoriasis studies&nbsp;1, 3 and 4 (ERASURE, FEATURE and JUNCTURE)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Week&nbsp;12</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week&nbsp;52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>150&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>300&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>150&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>300&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>150&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>300&nbsp;mg</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong><u>Study&nbsp;1</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>246</p></td><td style="vertical-align:top"><p>244</p></td><td style="vertical-align:top"><p>245</p></td><td style="vertical-align:top"><p>244</p></td><td style="vertical-align:top"><p>245</p></td><td style="vertical-align:top"><p>244</p></td><td style="vertical-align:top"><p>245</p></td></tr><tr><td style="vertical-align:top"><p>PASI 50 response n (%)</p></td><td style="vertical-align:top"><p>22 (8.9%)</p></td><td style="vertical-align:top"><p>203 (83.5%)</p></td><td style="vertical-align:top"><p>222 (90.6%)</p></td><td style="vertical-align:top"><p>212 (87.2%)</p></td><td style="vertical-align:top"><p>224 (91.4%)</p></td><td style="vertical-align:top"><p>187 (77%)</p></td><td style="vertical-align:top"><p>207 (84.5%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75 response n (%)</p></td><td style="vertical-align:top"><p>11 (4.5%)</p></td><td style="vertical-align:top"><p>174 (71.6%)<em>**</em></p></td><td style="vertical-align:top"><p>200 (81.6%)<em>**</em></p></td><td style="vertical-align:top"><p>188 (77.4%)</p></td><td style="vertical-align:top"><p>211 (86.1%)</p></td><td style="vertical-align:top"><p>146 (60.1%)</p></td><td style="vertical-align:top"><p>182 (74.3%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90 response n (%)</p></td><td style="vertical-align:top"><p>3 (1.2%)</p></td><td style="vertical-align:top"><p>95 (39.1%)<em>**</em></p></td><td style="vertical-align:top"><p>145 (59.2%)<em>**</em></p></td><td style="vertical-align:top"><p>130 (53.5%)</p></td><td style="vertical-align:top"><p>171 (69.8%)</p></td><td style="vertical-align:top"><p>88 (36.2%)</p></td><td style="vertical-align:top"><p>147 (60.0%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 100 response n (%)</p></td><td style="vertical-align:top"><p>2 (0.8%)</p></td><td style="vertical-align:top"><p>31 (12.8%)</p></td><td style="vertical-align:top"><p>70 (28.6%)</p></td><td style="vertical-align:top"><p>51 (21.0%)</p></td><td style="vertical-align:top"><p>102 (41.6%)</p></td><td style="vertical-align:top"><p>49 (20.2%)</p></td><td style="vertical-align:top"><p>96 (39.2%)</p></td></tr><tr><td style="vertical-align:top"><p>IGA mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>6 (2.40%)</p></td><td style="vertical-align:top"><p>125 (51.2%)<em>**</em></p></td><td style="vertical-align:top"><p>160 (65.3%)<em>**</em></p></td><td style="vertical-align:top"><p>142 (58.2%)</p></td><td style="vertical-align:top"><p>180 (73.5%)</p></td><td style="vertical-align:top"><p>101 (41.4%)</p></td><td style="vertical-align:top"><p>148 (60.4%)</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong><u>Study&nbsp;3</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 50 response n (%)</p></td><td style="vertical-align:top"><p>3 (5.1%)</p></td><td style="vertical-align:top"><p>51 (86.4%)</p></td><td style="vertical-align:top"><p>51 (87.9%)</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75 response n (%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>41 (69.5%)<em>**</em></p></td><td style="vertical-align:top"><p>44 (75.9%)<em>**</em></p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90 response n (%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>27 (45.8%)</p></td><td style="vertical-align:top"><p>35 (60.3%)</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 100 response n (%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>5</p><p>(8.5%)</p></td><td style="vertical-align:top"><p>25 (43.1%)</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>IGA mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>31 (52.5%)<em>**</em></p></td><td style="vertical-align:top"><p>40 (69.0%)<em>**</em></p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong><u>Study&nbsp;4</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 50 response n (%)</p></td><td style="vertical-align:top"><p>5 (8.2%)</p></td><td style="vertical-align:top"><p>48 (80.0%)</p></td><td style="vertical-align:top"><p>58 (96.7%)</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75 response n (%)</p></td><td style="vertical-align:top"><p>2 (3.3%)</p></td><td style="vertical-align:top"><p>43 (71.7%)<em>**</em></p></td><td style="vertical-align:top"><p>52 (86.7%)<em>**</em></p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90 response n (%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>24 (40.0%)</p></td><td style="vertical-align:top"><p>33 (55.0%)</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>PASI 100 response n(%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>10 (16.7%)</p></td><td style="vertical-align:top"><p>16 (26.7%)</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td style="vertical-align:top"><p>IGA mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>32 (53.3%)<em>**</em></p></td><td style="vertical-align:top"><p>44 (73.3%)<em>**</em></p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>‑</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p>* The IGA mod 2011 is a 5‑category scale including &ldquo;0 = clear&rdquo;, &ldquo;1 = almost clear&rdquo;, &ldquo;2 = mild&rdquo;, &ldquo;3 = moderate&rdquo; or &ldquo;4 = severe&rdquo;, indicating the physician&rsquo;s overall assessment of the psoriasis severity focusing on induration, erythema and scaling. Treatment success of &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; consisted of no signs of psoriasis or normal to pink colouration of lesions, no thickening of the plaque and none to minimal focal scaling.</p><p>** p‑values versus placebo and adjusted for multiplicity: p&lt;0.0001.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of clinical response on psoriasis study&nbsp;2 (FIXTURE)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:659px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Week 12</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Week 16</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Week 52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>150 mg</strong></p></td><td style="vertical-align:top"><p><strong>300 mg </strong></p></td><td style="vertical-align:top"><p><strong>Etanercept</strong></p></td><td style="vertical-align:top"><p><strong>150 mg</strong></p></td><td style="vertical-align:top"><p><strong>300 mg </strong></p></td><td style="vertical-align:top"><p><strong>Etanercept</strong></p></td><td style="vertical-align:top"><p><strong>150 mg</strong></p></td><td style="vertical-align:top"><p><strong>300 mg </strong></p></td><td style="vertical-align:top"><p><strong>Etanercept</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>324</p></td><td style="vertical-align:top"><p>327</p></td><td style="vertical-align:top"><p>323</p></td><td style="vertical-align:top"><p>323</p></td><td style="vertical-align:top"><p>327</p></td><td style="vertical-align:top"><p>323</p></td><td style="vertical-align:top"><p>323</p></td><td style="vertical-align:top"><p>327</p></td><td style="vertical-align:top"><p>323</p></td><td style="vertical-align:top"><p>323</p></td></tr><tr><td style="vertical-align:top"><p>PASI 50 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>49 (15.1%)</p></td><td style="vertical-align:top"><p>266 (81.3%)</p></td><td style="vertical-align:top"><p>296 (91.6%)</p></td><td style="vertical-align:top"><p>226 (70.0%)</p></td><td style="vertical-align:top"><p>290 (88.7%)</p></td><td style="vertical-align:top"><p>302 (93.5%)</p></td><td style="vertical-align:top"><p>257 (79.6%)</p></td><td style="vertical-align:top"><p>249 (76.1%)</p></td><td style="vertical-align:top"><p>274 (84.8%)</p></td><td style="vertical-align:top"><p>234 (72.4%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>16 (4.9%)</p></td><td style="vertical-align:top"><p>219 (67.0%)<em>**</em></p></td><td style="vertical-align:top"><p>249 (77.1%)<em>**</em></p></td><td style="vertical-align:top"><p>142 (44.0%)</p></td><td style="vertical-align:top"><p>247 (75.5%)</p></td><td style="vertical-align:top"><p>280 (86.7%)</p></td><td style="vertical-align:top"><p>189 (58.5%)</p></td><td style="vertical-align:top"><p>215 (65.7%)</p></td><td style="vertical-align:top"><p>254 (78.6%)</p></td><td style="vertical-align:top"><p>179 (55.4%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>5 (1.5%)</p></td><td style="vertical-align:top"><p>137 (41.9%)</p></td><td style="vertical-align:top"><p>175 (54.2%)</p></td><td style="vertical-align:top"><p>67 (20.7%)</p></td><td style="vertical-align:top"><p>176 (53.8%)</p></td><td style="vertical-align:top"><p>234 (72.4%)</p></td><td style="vertical-align:top"><p>101 (31.3%)</p></td><td style="vertical-align:top"><p>147 (45.0%)</p></td><td style="vertical-align:top"><p>210 (65.0%)</p></td><td style="vertical-align:top"><p>108 (33.4%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 100 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>0 (0%)</p></td><td style="vertical-align:top"><p>47 (14.4%)</p></td><td style="vertical-align:top"><p>78 (24.1%)</p></td><td style="vertical-align:top"><p>14 (4.3%)</p></td><td style="vertical-align:top"><p>84 (25.7%)</p></td><td style="vertical-align:top"><p>119 (36.8%)</p></td><td style="vertical-align:top"><p>24 (7.4%)</p></td><td style="vertical-align:top"><p>65 (19.9%)</p></td><td style="vertical-align:top"><p>117 (36.2%)</p></td><td style="vertical-align:top"><p>32 (9.9%)</p></td></tr><tr><td style="vertical-align:top"><p>IGA mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>9 (2.8%)</p></td><td style="vertical-align:top"><p>167 (51.1%)<em>**</em></p></td><td style="vertical-align:top"><p>202 (62.5%)<em>**</em></p></td><td style="vertical-align:top"><p>88 (27.2%)</p></td><td style="vertical-align:top"><p>200 (61.2%)</p></td><td style="vertical-align:top"><p>244 (75.5%)</p></td><td style="vertical-align:top"><p>127 (39.3%)</p></td><td style="vertical-align:top"><p>168 (51.4%)</p></td><td style="vertical-align:top"><p>219 (67.8%)</p></td><td style="vertical-align:top"><p>120 (37.2%)</p></td></tr></tbody></table><p>** p‑values versus etanercept: p=0.0250</p><p>&nbsp;</p><p>In an additional psoriasis study (CLEAR) 676&nbsp;patients were evaluated. Secukinumab 300&nbsp;mg met the primary and secondary endpoints by showing superiority to ustekinumab based on PASI&nbsp;90 response at week&nbsp;16 (primary endpoint), speed of onset of PASI&nbsp;75 response at week&nbsp;4, and long-term PASI&nbsp;90 response at week&nbsp;52. Greater efficacy of secukinumab compared to ustekinumab for the endpoints PASI&nbsp;75/90/100 and IGA mod 2011 0 or 1 response (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) was observed early and continued through to week&nbsp;52 (Table&nbsp;6).</p><p>&nbsp;</p><p><strong>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of clinical response on CLEAR study</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:635px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>Week&nbsp;4</strong></p></td><td colspan="2"><p><strong>Week&nbsp;16</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week&nbsp;52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab 300&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Ustekinumab*</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab 300&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Ustekinumab*</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab 300&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Ustekinumab*</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>334</p></td><td style="vertical-align:top"><p>335</p></td><td style="vertical-align:top"><p>334</p></td><td style="vertical-align:top"><p>335</p></td><td style="vertical-align:top"><p>334</p></td><td style="vertical-align:top"><p>335</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>166 (49.7%)**</p></td><td style="vertical-align:top"><p>69 (20.6%)</p></td><td style="vertical-align:top"><p>311 (93.1%)</p></td><td style="vertical-align:top"><p>276 (82.4%)</p></td><td style="vertical-align:top"><p>306 (91.6%)</p></td><td style="vertical-align:top"><p>262 (78.2%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>70 (21.0%)</p></td><td style="vertical-align:top"><p>18 (5.4%)</p></td><td style="vertical-align:top"><p>264 (79.0%)**</p></td><td style="vertical-align:top"><p>192 (57.3%)</p></td><td style="vertical-align:top"><p>250 (74.9%)***</p></td><td style="vertical-align:top"><p>203 (60.6%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 100 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>14 (4.2%)</p></td><td style="vertical-align:top"><p>3 (0.9%)</p></td><td style="vertical-align:top"><p>148 (44.3%)</p></td><td style="vertical-align:top"><p>95 (28.4%)</p></td><td style="vertical-align:top"><p>150 (44.9%)</p></td><td style="vertical-align:top"><p>123 (36.7%)</p></td></tr><tr><td style="vertical-align:top"><p>IGA mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>128 (38.3%)</p></td><td style="vertical-align:top"><p>41 (12.2%)</p></td><td style="vertical-align:top"><p>278 (83.2%)</p></td><td style="vertical-align:top"><p>226 (67.5%)</p></td><td style="vertical-align:top"><p>261 (78.1%)</p></td><td style="vertical-align:top"><p>213 (63.6%)</p></td></tr></tbody></table><p>* Patients treated with secukinumab received 300&nbsp;mg doses at weeks&nbsp;0, 1, 2 3 and 4, followed by the same dose every 4&nbsp;weeks until week&nbsp;52. Patients treated with ustekinumab received 45&nbsp;mg or 90&nbsp;mg at weeks&nbsp;0 and 4, then every 12&nbsp;weeks until week&nbsp;52 (dosed by weight as per approved posology)</p><p>** p‑values versus ustekinumab: p&lt;0.0001 for primary endpoint of PASI&nbsp;90 at week&nbsp;16 and secondary endpoint of PASI&nbsp;75 at week&nbsp;4</p><p>*** p‑values versus ustekinumab: p=0.0001 for secondary endpoint of PASI&nbsp;90 at week&nbsp;52</p><p>&nbsp;</p><p>Secukinumab was efficacious in systemic treatment-naive, biologic‑naive, biologic/anti‑TNF‑exposed and biologic/anti‑TNF‑failure patients. Improvements in PASI 75 in patients with concurrent psoriatic arthritis at baseline were similar to those in the overall plaque psoriasis population.</p><p>Secukinumab was associated with a fast onset of efficacy with a 50% reduction in mean PASI by week&nbsp;3 for the 300&nbsp;mg dose.</p><p>&nbsp;</p><p><strong>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Time course of percentage change from baseline of mean PASI score in study&nbsp;1 (ERASURE)</strong></p><p><br /><img src="data:image/png;base64,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" alt="" width="816" height="393" vspace="0" hspace="0" border="0" style="width:816px;height:393px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><em>Specific locations/forms of plaque psoriasis</em></p><p>In two additional placebo-controlled studies, improvement was seen in both nail psoriasis (TRANSFIGURE, 198&nbsp;patients) and palmoplantar plaque psoriasis (GESTURE, 205&nbsp;patients). In the TRANSFIGURE study, secukinumab was superior to placebo at week&nbsp;16 (46.1% for 300&nbsp;mg, 38.4% for 150&nbsp;mg and 11.7% for placebo) as assessed by significant improvement from baseline in the Nail Psoriasis Severity Index (NAPSI %) for patients with moderate to severe plaque psoriasis with nail involvement. In the GESTURE study, secukinumab was superior to placebo at week&nbsp;16 (33.3% for 300&nbsp;mg, 22.1% for 150&nbsp;mg, and 1.5% for placebo) as assessed by significant improvement of ppIGA 0 or 1 response (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) for patients with moderate to severe palmoplantar plaque psoriasis.</p><p>&nbsp;</p><p>A placebo-controlled study evaluated 102&nbsp;patients with moderate to severe scalp psoriasis, defined as having a Psoriasis Scalp Severity Index (PSSI) score of &ge;12, an IGA mod 2011 scalp only score of 3 or greater and at least 30% of the scalp surface area affected. Secukinumab 300&nbsp;mg was superior to placebo at week&nbsp;12 as assessed by significant improvement from baseline in both the PSSI&nbsp;90 response (52.9% versus 2.0%) and IGA mod 2011 0 or 1 scalp only response (56.9% versus 5.9%). Improvement in both endpoints was sustained for secukinumab patients who continued treatment through to week&nbsp;24.</p><p>&nbsp;</p><p><em>Quality of life/patient‑reported outcomes</em></p><p>Statistically significant improvements at week&nbsp;12 (studies&nbsp;1‑4) from baseline compared to placebo were demonstrated in the DLQI (Dermatology Life Quality Index). Mean decreases (improvements) in DLQI from baseline ranged from ‑10.4 to ‑11.6 with secukinumab 300&nbsp;mg, from ‑7.7 to ‑10.1 with secukinumab 150&nbsp;mg, versus ‑1.1 to ‑1.9 for placebo at week&nbsp;12. These improvements were maintained for 52&nbsp;weeks (studies&nbsp;1&nbsp;and&nbsp;2).</p><p>&nbsp;</p><p>Forty percent of the participants in studies&nbsp;1 and 2 completed the Psoriasis Symptom Diary<sup>&copy;</sup>. For the</p><p>participants completing the diary in each of these studies, statistically significant improvements at week&nbsp;12 from baseline compared to placebo in patient‑reported signs and symptoms of itching, pain and scaling were demonstrated.</p><p>&nbsp;</p><p>Statistically significant improvements at week&nbsp;4 from baseline in patients treated with secukinumab compared to patients treated with ustekinumab (CLEAR) were demonstrated in the DLQI and these improvements were maintained for up to 52&nbsp;weeks.</p><p>&nbsp;</p><p>Statistically significant improvements in patient-reported signs and symptoms of itching, pain and scaling at week&nbsp;16 and week&nbsp;52 (CLEAR) were demonstrated in the Psoriasis Symptom Diary<sup>&copy;</sup> in patients treated with secukinumab compared to patients treated with ustekinumab.</p><p>&nbsp;</p><p>Statistically significant improvements (decreases) at week&nbsp;12 from baseline in the scalp psoriasis study were demonstrated in patient reported signs and symptoms of scalp itching, pain and scaling compared to placebo.</p><p><em>&nbsp;</em></p><p><em>Plaque psoriasis dose flexibility</em></p><p>A randomised, double-blind, multicentre study evaluated two maintenance dosing regimens (300&nbsp;mg every 2&nbsp;weeks [Q2W] and 300&nbsp;mg every 4&nbsp;weeks [Q4W]) administered by 150&nbsp;mg pre-filled syringe in 331&nbsp;patients weighing &ge;90&nbsp;kg with moderate to severe psoriasis. Patients were randomised 1:1 as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; secukinumab 300&nbsp;mg at weeks&nbsp;0, 1, 2, 3, and 4 followed by the same dose every 2&nbsp;weeks (Q2W) up to week&nbsp;52 (n=165).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; secukinumab 300&nbsp;mg at weeks&nbsp;0, 1, 2, 3, and 4 followed by the same dose every 4&nbsp;weeks (Q4W) up to week&nbsp;16 (n=166).</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients randomised to receive secukinumab 300&nbsp;mg Q4W who were PASI&nbsp;90 responders at week&nbsp;16 continued to receive the same dosing regimen up to week&nbsp;52. Patients randomised to receive secukinumab 300&nbsp;mg Q4W who were PASI&nbsp;90 non-responders at week&nbsp;16 either continued on the same dosing regimen, or were reassigned to receive secukinumab 300&nbsp;mg Q2W up to week&nbsp;52.</p><p>Overall, the efficacy response rates for the group treated with the every 2&nbsp;weeks regimen were higher compared to the group treated with the every 4&nbsp;weeks regimen (Table&nbsp;7).</p><p>&nbsp;</p><p><strong>Table&nbsp;7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of clinical response in the plaque psoriasis dose flexibility study*</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>Week&nbsp;16</strong></p></td><td colspan="2"><p><strong>Week&nbsp;52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>secukinumab 300&nbsp;mg Q2W</strong></p></td><td style="vertical-align:top"><p><strong>secukinumab 300&nbsp;mg Q4W</strong></p></td><td style="vertical-align:top"><p><strong>secukinumab 300&nbsp;mg Q2W</strong></p></td><td style="vertical-align:top"><p><strong>secukinumab 300&nbsp;mg Q4W</strong><sup>1</sup></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>165</p></td><td style="vertical-align:top"><p>166</p></td><td style="vertical-align:top"><p>165</p></td><td style="vertical-align:top"><p>83</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90 response n (%)</p></td><td style="vertical-align:top"><p>121 (73.2%) **</p></td><td style="vertical-align:top"><p>92 (55.5%)</p></td><td style="vertical-align:top"><p>126 (76.4%)</p></td><td style="vertical-align:top"><p>44 (52.4%)</p></td></tr><tr><td style="vertical-align:top"><p>IGA mod 2011 &ldquo;clear&rdquo; or &ldquo;almost clear&rdquo; response n (%)</p></td><td style="vertical-align:top"><p>122 (74.2%)<sup>2</sup></p></td><td style="vertical-align:top"><p>109 (65.9%)<sup>2</sup></p></td><td style="vertical-align:top"><p>125 (75.9%)</p></td><td style="vertical-align:top"><p>46 (55.6%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* Multiple imputation</p><p><sup>1</sup> 300&nbsp;mg Q4W:patients continuously treated with 300&nbsp;mg Q4W regardless of PASI 90 response status at week&nbsp;16; 43 patients were PASI 90 responder at week&nbsp;16 and 40 patients were PASI 90 non-responders at week&nbsp;16</p><p>** One sided p-value = 0.0003 for primary endpoint of PASI 90 at week&nbsp;16</p><p><sup>2</sup> Not statistically significant</p></td></tr></tbody></table><p>In the PASI&nbsp;90 non-responders at week&nbsp;16 who were up-titrated to secukinumab 300&nbsp;mg Q2W, the PASI&nbsp;90 response rates improved compared to those who remained on the secukinumab 300&nbsp;mg Q4W dosing regimen, while the IGA mod 2011 0/1 response rates remained stable over time in both treatment groups.</p><p>&nbsp;</p><p>The safety profiles of the two dosing regimens, Cosentyx 300&nbsp;mg administered every 4&nbsp;weeks and Cosentyx 300&nbsp;mg administered every 2&nbsp;weeks, in patients weighing &ge;90&nbsp;kg were comparable and consistent with the safety profile reported in psoriasis patients.</p><p>&nbsp;</p><p><em><u>Hidradenitis suppurativa</u></em></p><p>The safety and efficacy of secukinumab were assessed in 1084&nbsp;patients in two randomised, double‑blind, placebo‑controlled phase&nbsp;III studies in adult patients with moderate to severe hidradenitis suppurativa (HS) who were candidates for systemic biologic therapy. Patients were required to have at least five inflammatory lesions affecting at least two anatomical areas at baseline. In HS study&nbsp;1 (SUNSHINE) and HS study&nbsp;2 (SUNRISE), respectively, 4.6% and 2.8% of patients were Hurley stage&nbsp;I, 61.4% and 56.7% were Hurley stage&nbsp;II, and 34.0% and 40.5% were Hurley stage&nbsp;III.The proportion of patients weighing &ge;90&nbsp;kg was 54.7% in HS study&nbsp;1 and 50.8% in HS study&nbsp;2. Patients in these studies had a diagnosis of moderate to severe HS for a mean of 7.3&nbsp;years and 56.3% of the study participants were female.</p><p>&nbsp;</p><p>In HS study&nbsp;1 and HS study&nbsp;2, 23,8% and 23,2% of patients, respectively, were previously treated with a biologic. 82.3% and 83.6% of patients, respectively, were previously treated with systemic antibiotics.</p><p>&nbsp;</p><p>HS study&nbsp;1 evaluated 541&nbsp;patients and HS study&nbsp;2 evaluated 543&nbsp;patients, of whom 12.8% and 10.7%, respectively, received concomitant stable‑dose antibiotics. In both studies, patients randomised to secukinumab received 300&nbsp;mg subcutaneously at weeks&nbsp;0, 1, 2, 3 and 4, followed by 300&nbsp;mg every 2&nbsp;weeks (Q2W) or every 4&nbsp;weeks (Q4W). At week&nbsp;16, patients who were randomised to placebo were reassigned to receive secukinumab 300&nbsp;mg at weeks&nbsp;16, 17, 18, 19 and 20 followed by either secukinumab 300&nbsp;mg Q2W or secukinumab 300&nbsp;mg Q4W.</p><p>&nbsp;</p><p>The primary endpoint in both studies (HS study&nbsp;1 and HS study&nbsp;2) was the proportion of patients achieving a Hidradenitis Suppurativa Clinical Response defined as at least a 50% decrease in abscesses and inflammatory nodules count with no increase in the number of abscesses and/or in the number of draining fistulae relative to baseline (HiSCR50) at week&nbsp;16. Reduction in HS‑related skin pain was assessed as a secondary endpoint on the pooled data of HS study&nbsp;1 and HS study&nbsp;2 using a Numerical Rating Scale (NRS) in patients who entered the studies with an initial baseline score of 3 or greater.</p><p>&nbsp;</p><p>In HS study&nbsp;1 and HS study&nbsp;2, a higher proportion of patients treated with secukinumab 300&nbsp;mg Q2W achieved a HiSCR50 response with a decrease in abscesses and inflammatory nodules (AN) count compared to placebo at week&nbsp;16. In HS study&nbsp;2, a difference in HiSCR50 response and AN count was also observed with the secukinumab 300&nbsp;mg Q4W regimen. In the secukinumab 300&nbsp;mg Q2W group in HS study&nbsp;1 and in the secukinumab 300&nbsp;mg Q4W group in HS study&nbsp;2, a lower rate of patients experienced flares compared to placebo up to week&nbsp;16. A higher proportion of patients treated with secukinumab 300&nbsp;mg Q2W (pooled data) experienced a clinically relevant decrease in HS-related skin pain compared to placebo at week&nbsp;16 (Table&nbsp;8).</p><p><strong>Table&nbsp;8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical response in HS study&nbsp;1 and HS study&nbsp;2 at week&nbsp;16<sup>1</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>HS study&nbsp;1</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>HS study&nbsp;2</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>300&nbsp;mg Q4W</p></td><td style="vertical-align:top"><p>300&nbsp;mg Q2W</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>300&nbsp;mg Q4W</p></td><td style="vertical-align:top"><p>300&nbsp;mg Q2W</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of patients randomised</strong></p></td><td style="vertical-align:top"><p>180</p></td><td style="vertical-align:top"><p>180</p></td><td style="vertical-align:top"><p>181</p></td><td style="vertical-align:top"><p>183</p></td><td style="vertical-align:top"><p>180</p></td><td style="vertical-align:top"><p>180</p></td></tr><tr><td style="vertical-align:top"><p>HiSCR50, n (%)</p></td><td style="vertical-align:top"><p>61</p><p>(33.7)</p></td><td style="vertical-align:top"><p>75</p><p>(41.8)</p></td><td style="vertical-align:top"><p>82</p><p>(45.0*)</p></td><td style="vertical-align:top"><p>57</p><p>(31.2)</p></td><td style="vertical-align:top"><p>83</p><p>(46.1*)</p></td><td style="vertical-align:top"><p>76</p><p>(42.3*)</p></td></tr><tr><td style="vertical-align:top"><p>AN count, mean % change from baseline</p></td><td style="vertical-align:top"><p>‑24.3</p></td><td style="vertical-align:top"><p>‑42.4</p></td><td style="vertical-align:top"><p>‑46.8*</p></td><td style="vertical-align:top"><p>‑22.4</p></td><td style="vertical-align:top"><p>‑45.5*</p></td><td style="vertical-align:top"><p>‑39.3*</p></td></tr><tr><td style="vertical-align:top"><p>Flares, n (%)</p></td><td style="vertical-align:top"><p>52</p><p>(29.0)</p></td><td style="vertical-align:top"><p>42</p><p>(23.2)</p></td><td style="vertical-align:top"><p>28</p><p>(15.4*)</p></td><td style="vertical-align:top"><p>50</p><p>(27.0)</p></td><td style="vertical-align:top"><p>28</p><p>(15.6*)</p></td><td style="vertical-align:top"><p>36</p><p>(20.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p><strong>Pooled data (HS study&nbsp;1 and HS study&nbsp;2)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>300&nbsp;mg Q4W</p></td><td colspan="2" style="vertical-align:top"><p>300&nbsp;mg Q2W</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of patients with NRS &ge;3 at baseline</strong></p></td><td colspan="2" style="vertical-align:top"><p>251</p></td><td colspan="2" style="vertical-align:top"><p>252</p></td><td colspan="2" style="vertical-align:top"><p>266</p></td></tr><tr><td style="vertical-align:top"><p>&ge;30% reduction in skin pain, NRS30 response, n (%)</p></td><td colspan="2" style="vertical-align:top"><p>58 (23.0)</p></td><td colspan="2" style="vertical-align:top"><p>84 (33.5)</p></td><td colspan="2" style="vertical-align:top"><p>97 (36.6*)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>1</sup> Multiple imputation was implemented to handle missing data</p><p>n: Rounded average number of subjects with responses in 100&nbsp;imputations</p><p>*Statistically significant versus placebo based on the pre‑defined hierarchy with overall alpha=0.05</p><p>AN: Abscesses and inflammatory Nodules; HiSCR: Hidradenitis Suppurativa Clinical Response; NRS: Numerical Rating Scale</p></td></tr></tbody></table><p>&nbsp;</p><p>In both studies, the onset of action of secukinumab occurred as early as week&nbsp;2, the efficacy progressively increased to week&nbsp;16 and was maintained up to week&nbsp;52.</p><p>&nbsp;</p><p>Improvements were seen for the primary and key secondary endpoints in HS patients regardless of previous or concomitant antibiotic treatment.</p><p>&nbsp;</p><p>HiSCR50 responses were improved at week&nbsp;16 in both biologic‑na&iuml;ve and biologic‑exposed patients.</p><p>&nbsp;</p><p>Greater improvements at week&nbsp;16 from baseline compared to placebo were demonstrated in health‑related quality of life as measured by the Dermatology Life Quality Index.</p><p>&nbsp;</p><p><em><u>Psoriatic arthritis</u></em></p><p>The safety and efficacy of secukinumab were assessed in 1999&nbsp;patients in three randomised, double‑blind, placebo‑controlled phase III studies in patients with active psoriatic arthritis (&ge;3&nbsp;swollen and &ge;3&nbsp;tender joints) despite non‑steroidal anti‑inflammatory drug (NSAID), corticosteroid or disease‑modifying anti‑rheumatic drug (DMARD) therapy. Patients with each subtype of PsA were enrolled in these studies, including polyarticular arthritis with no evidence of rheumatoid nodules, spondylitis with peripheral arthritis, asymmetric peripheral arthritis, distal interphalangeal involvement and arthritis mutilans. Patients in these studies had a diagnosis of PsA of at least five years. The majority of patients also had active psoriasis skin lesions or a documented history of psoriasis. Over 61% and 42% of the PsA patients had enthesitis and dactylitis at baseline, respectively. For all studies, the primary endpoint was American College of Rheumatology (ACR) 20 response. For Psoriatic Arthritis study&nbsp;1 (PsA study&nbsp;1) and Psoriatic Arthritis study&nbsp;2 (PsA study&nbsp;2), the primary endpoint was at week&nbsp;24. For Psoriatic Arthritis study&nbsp;3 (PsA</p><p>study&nbsp;3), the primary endpoint was at week&nbsp;16 with the key secondary endpoint, the change from baseline in modified Total Sharp Score (mTSS), at week&nbsp;24.</p><p>&nbsp;</p><p>In PsA study&nbsp;1, PsA study&nbsp;2 and PsA study&nbsp;3, 29%, 35% and 30% of patients, respectively, were previously treated with an anti‑TNF&alpha; agent and discontinued the anti-TNF&alpha; agent for either lack of efficacy or intolerance (anti-TNF&alpha;-IR patients).</p><p>&nbsp;</p><p>PsA study&nbsp;1 (FUTURE&nbsp;1) evaluated 606&nbsp;patients, of whom 60.7% had concomitant MTX. Patients randomised to secukinumab received 10&nbsp;mg/kg intravenously at weeks&nbsp;0, 2, and 4, followed by either 75&nbsp;mg or 150&nbsp;mg subcutaneously every month starting at week&nbsp;8. Patients randomised to placebo who were non‑responders at week&nbsp;16 (early rescue) and other placebo patients at week&nbsp;24 were crossed over to receive secukinumab (either 75&nbsp;mg or 150&nbsp;mg subcutaneously) followed by the same dose every month.</p><p>&nbsp;</p><p>PsA study&nbsp;2 (FUTURE&nbsp;2) evaluated 397&nbsp;patients, of whom 46.6% had concomitant MTX. Patients randomised to secukinumab received 75&nbsp;mg, 150&nbsp;mg or 300&nbsp;mg subcutaneously at weeks&nbsp;0, 1, 2, 3 and 4, followed by the same dose every month. Patients randomised to receive placebo who were non‑responders at week&nbsp;16 (early rescue) were crossed over to receive secukinumab (either 150&nbsp;mg or 300&nbsp;mg subcutaneously) at week&nbsp;16 followed by the same dose every month. Patients randomised to receive placebo who were responders at week&nbsp;16 were crossed over to receive secukinumab (either 150&nbsp;mg or 300&nbsp;mg subcutaneously) at week&nbsp;24 followed by the same dose every month.</p><p>&nbsp;</p><p>PsA study&nbsp;3 (FUTURE&nbsp;5) evaluated 996&nbsp;patients, of whom 50.1% had concomitant MTX. Patients were randomised to receive secukinumab 150&nbsp;mg, 300&nbsp;mg or placebo subcutaneously at weeks&nbsp;0, 1, 2, 3 and 4, followed by the same dose every month, or a once monthly injection of secukinumab 150&nbsp;mg (without loading). Patients randomised to receive placebo who were non-responders at week&nbsp;16 (early rescue) were then crossed over to receive secukinumab (either 150&nbsp;mg or 300&nbsp;mg subcutaneously) at week&nbsp;16 followed by the same dose every month. Patients randomised to receive placebo who were responders at week&nbsp;16 were crossed over to receive secukinumab (either 150&nbsp;mg or 300&nbsp;mg subcutaneously) at week&nbsp;24 followed by the same dose every month.</p><p>&nbsp;</p><p><em>Signs and symptoms</em></p><p>Treatment with secukinumab resulted in significant improvement in measures of disease activity compared to placebo at weeks&nbsp;16 and 24 (see Table&nbsp;9).</p><p><strong>Table&nbsp;9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical response in PsA study&nbsp;2 and PsA study&nbsp;3 at week&nbsp;16 and week&nbsp;24</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>PsA study&nbsp;2</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>PsA study&nbsp;3</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>150&nbsp;mg<strong><sup>1</sup></strong></p></td><td style="vertical-align:top"><p>300&nbsp;mg<strong><sup>1</sup></strong></p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>150&nbsp;mg<strong><sup>1</sup></strong></p></td><td style="vertical-align:top"><p>300&nbsp;mg<strong><sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of patients randomised</strong></p></td><td style="vertical-align:top"><p>98</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>332</p></td><td style="vertical-align:top"><p>220</p></td><td style="vertical-align:top"><p>222</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR20 response</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>18</p><p>(18.4%)</p></td><td style="vertical-align:top"><p>60</p><p>(60.0%***)</p></td><td style="vertical-align:top"><p>57</p><p>(57.0%***)</p></td><td style="vertical-align:top"><p>91<sup>&loz;</sup></p><p>(27.4%)</p></td><td style="vertical-align:top"><p>122<sup>&loz;</sup></p><p>(55.5%***)</p></td><td style="vertical-align:top"><p>139<sup>&loz;</sup></p><p>(62.6%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>15<sup>&loz;</sup></p><p>(15.3%)</p></td><td style="vertical-align:top"><p>51<sup>&loz;</sup></p><p>(51.0%***)</p></td><td style="vertical-align:top"><p>54<sup>&loz;</sup></p><p>(54.0%***)</p></td><td style="vertical-align:top"><p>78</p><p>(23.5%)</p></td><td style="vertical-align:top"><p>117</p><p>(53.2%***)</p></td><td style="vertical-align:top"><p>141</p><p>(63.5%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR50 response</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>6</p><p>(6.1%)</p></td><td style="vertical-align:top"><p>37</p><p>(37.0%***)</p></td><td style="vertical-align:top"><p>35</p><p>(35.0%***)</p></td><td style="vertical-align:top"><p>27</p><p>(8.1%)</p></td><td style="vertical-align:top"><p>79</p><p>(35.9%*)</p></td><td style="vertical-align:top"><p>88</p><p>(39.6%*)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>7</p><p>(7.1%)</p></td><td style="vertical-align:top"><p>35</p><p>(35.0%)</p></td><td style="vertical-align:top"><p>35</p><p>(35.0%**)</p></td><td style="vertical-align:top"><p>29</p><p>(8.7%)</p></td><td style="vertical-align:top"><p>86</p><p>(39.1%***)</p></td><td style="vertical-align:top"><p>97</p><p>(43.7%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ACR70 response</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>2</p><p>(2.0%)</p></td><td style="vertical-align:top"><p>17</p><p>(17.0%**)</p></td><td style="vertical-align:top"><p>15</p><p>(15.0%**)</p></td><td style="vertical-align:top"><p>14</p><p>(4.2%)</p></td><td style="vertical-align:top"><p>40</p><p>(18.2%***)</p></td><td style="vertical-align:top"><p>45</p><p>(20.3%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>1</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>21</p><p>(21.0%**)</p></td><td style="vertical-align:top"><p>20</p><p>(20.0%**)</p></td><td style="vertical-align:top"><p>13</p><p>(3.9%)</p></td><td style="vertical-align:top"><p>53</p><p>(24.1%***)</p></td><td style="vertical-align:top"><p>57</p><p>(25.7%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>DAS28‑CRP</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>-0.50</p></td><td style="vertical-align:top"><p>-1.45***</p></td><td style="vertical-align:top"><p>-1.51***</p></td><td style="vertical-align:top"><p>-0.63</p></td><td style="vertical-align:top"><p>-1.29*</p></td><td style="vertical-align:top"><p>-1.49*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>-0.96</p></td><td style="vertical-align:top"><p>-1.58**</p></td><td style="vertical-align:top"><p>-1.61**</p></td><td style="vertical-align:top"><p>-0.84</p></td><td style="vertical-align:top"><p>-1.57***</p></td><td style="vertical-align:top"><p>-1.68***</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of patients with &ge;3% BSA psoriasis skin involvement at baseline</strong></p></td><td style="vertical-align:top"><p>43</p><p>(43.9%)</p></td><td style="vertical-align:top"><p>58</p><p>(58.0%)</p></td><td style="vertical-align:top"><p>41</p><p>(41.0%)</p></td><td style="vertical-align:top"><p>162</p><p>(48.8%)</p></td><td style="vertical-align:top"><p>125</p><p>(56.8%)</p></td><td style="vertical-align:top"><p>110</p><p>(49.5%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 75 response</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>3</p><p>(7.0%)</p></td><td style="vertical-align:top"><p>33</p><p>(56.9%***)</p></td><td style="vertical-align:top"><p>27</p><p>(65.9%***)</p></td><td style="vertical-align:top"><p>20</p><p>(12.3%)</p></td><td style="vertical-align:top"><p>75</p><p>(60.0%*)</p></td><td style="vertical-align:top"><p>77</p><p>(70.0%*)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>7</p><p>(16.3%)</p></td><td style="vertical-align:top"><p>28</p><p>(48.3%**)</p></td><td style="vertical-align:top"><p>26</p><p>(63.4%***)</p></td><td style="vertical-align:top"><p>29</p><p>(17.9%)</p></td><td style="vertical-align:top"><p>80</p><p>(64.0%***)</p></td><td style="vertical-align:top"><p>78</p><p>(70.9%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 90 response</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>3</p><p>(7.0%)</p></td><td style="vertical-align:top"><p>22</p><p>(37.9%***)</p></td><td style="vertical-align:top"><p>18</p><p>(43.9%***)</p></td><td style="vertical-align:top"><p>15</p><p>(9.3%)</p></td><td style="vertical-align:top"><p>46</p><p>(36.8%*)</p></td><td style="vertical-align:top"><p>59</p><p>(53.6%*)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>4</p><p>(9.3%)</p></td><td style="vertical-align:top"><p>19</p><p>(32.8%**)</p></td><td style="vertical-align:top"><p>20</p><p>(48.8%***)</p></td><td style="vertical-align:top"><p>19</p><p>(11.7%)</p></td><td style="vertical-align:top"><p>51</p><p>(40.8%***)</p></td><td style="vertical-align:top"><p>60</p><p>(54.5%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dactylitis resolution n (%) &dagger;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>10</p><p>(37%)</p></td><td style="vertical-align:top"><p>21</p><p>(65.6%*)</p></td><td style="vertical-align:top"><p>26</p><p>(56.5%)</p></td><td style="vertical-align:top"><p>40</p><p>(32.3%)</p></td><td style="vertical-align:top"><p>46</p><p>(57.5%*)</p></td><td style="vertical-align:top"><p>54</p><p>(65.9%*)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>4</p><p>(14.8%)</p></td><td style="vertical-align:top"><p>16</p><p>(50.0%**)</p></td><td style="vertical-align:top"><p>26</p><p>(56.5%**)</p></td><td style="vertical-align:top"><p>42</p><p>(33.9%)</p></td><td style="vertical-align:top"><p>51</p><p>(63.8%***)</p></td><td style="vertical-align:top"><p>52</p><p>(63.4%***)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Enthesitis resolution n (%) &Dagger;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;16</strong></p></td><td style="vertical-align:top"><p>17</p><p>(26.2%)</p></td><td style="vertical-align:top"><p>32</p><p>(50.0%**)</p></td><td style="vertical-align:top"><p>32</p><p>(57.1%***)</p></td><td style="vertical-align:top"><p>68</p><p>(35.4%)</p></td><td style="vertical-align:top"><p>77</p><p>(54.6%*)</p></td><td style="vertical-align:top"><p>78</p><p>(55.7%*)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>14</p><p>(21.5%)</p></td><td style="vertical-align:top"><p>27</p><p>(42.2%*)</p></td><td style="vertical-align:top"><p>27</p><p>(48.2%**)</p></td><td style="vertical-align:top"><p>66</p><p>(34.4%)</p></td><td style="vertical-align:top"><p>77</p><p>(54.6%***)</p></td><td style="vertical-align:top"><p>86</p><p>(61.4%***)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>* p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001; versus placebo</p><p>All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy at week&nbsp;24 for PsA study&nbsp;2, except for ACR70, Dactylitis and Enthesitis, which were exploratory endpoints and all endpoints at week&nbsp;16.</p><p>All p‑values are adjusted for multiplicity of testing based on pre-defined hierarchy at week&nbsp;16 for PsA study&nbsp;3, except for ACR70 which was an exploratory endpoint and all endpoints at week&nbsp;24.</p><p>Non‑responder imputation used for missing binary endpoint.</p><p>ACR: American College of Rheumatology; PASI: Psoriasis Area and Severity Index; DAS: Disease Activity Score; BSA: Body Surface Area</p><p><sup>&loz;</sup>Primary Endpoint</p><p><sup>1</sup>Secukinumab 150&nbsp;mg or 300&nbsp;mg s.c. at weeks&nbsp;0, 1, 2, 3, and 4 followed by the same dose every month</p><p>&dagger;In patients with dactylitis at baseline (n=27, 32, 46, respectively for PsA study&nbsp;2 and n=124, 80, 82, respectively for PsA study&nbsp;3)</p><p>&Dagger;In patients with enthesitis at baseline (n=65, 64, 56, respectively for PsA study&nbsp;2 and n=192, 141, 140, respectively for PsA study&nbsp;3)</p></td></tr></tbody></table><p>&nbsp;</p><p>The onset of action of secukinumab occurred as early as week&nbsp;2. Statistically significant difference in ACR 20 versus placebo was reached at week&nbsp;3.</p><p>&nbsp;</p><p>The percentage of patients achieving ACR 20 response by visit is shown in Figure&nbsp;2.</p><p><strong>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACR20 response in PsA study&nbsp;2 over time up to week&nbsp;52</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="824" height="509" vspace="0" hspace="0" border="0" style="width:824px;height:509px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Similar responses for primary and key secondary endpoints were seen in PsA patients regardless of whether they were on concomitant MTX treatment or not. In PsA study&nbsp;2, at week&nbsp;24, secukinumab-treated patients with concomitant MTX use had a higher ACR&nbsp;20 response (47.7% and 54.4% for 150&nbsp;mg and 300&nbsp;mg, respectively, compared to placebo 20.0%) and ACR&nbsp;50 response (31.8% and 38.6% for 150&nbsp;mg and 300&nbsp;mg, respectively, compared to placebo 8.0%). Secukinumab-treated patients without concomitant MTX use had a higher ACR&nbsp;20 response (53.6% and 53.6% for 150&nbsp;mg and 300&nbsp;mg, respectively, compared to placebo 10.4%) and ACR&nbsp;50 response (37.5% and 32.1% for 150&nbsp;mg and 300&nbsp;mg, respectively, compared to placebo 6.3%).</p><p>&nbsp;</p><p>In PsA study&nbsp;2, both anti‑TNF&alpha;‑naive and anti‑TNF&alpha;‑IR secukinumab-treated patients had a significantly higher ACR 20 response compared to placebo at week&nbsp;24, with a slightly higher response in the anti‑TNF&alpha;‑naive group (anti‑TNF&alpha;‑naive: 64% and 58% for 150&nbsp;mg and 300&nbsp;mg, respectively, compared to placebo 15.9%; anti‑TNF&alpha;‑IR: 30% and 46% for 150&nbsp;mg and 300&nbsp;mg, respectively, compared to placebo 14.3%). In the anti-TNF&alpha;-IR patients subgroup, only the 300&nbsp;mg dose showed significantly higher response rate for ACR&nbsp;20 compared to placebo (p&lt;0.05) and demonstrated clinical meaningful benefit over 150&nbsp;mg on multiple secondary endpoints. Improvements in the PASI&nbsp;75 response were seen in both subgroups and the 300&nbsp;mg dose showed statistically significant benefit in the anti‑TNF&alpha;-IR patients.</p><p><u>&nbsp;</u></p><p>Improvements were shown in all components of the ACR scores, including patient assessment of pain. In PsA study&nbsp;2, the proportion of patients achieving a modified PsA Response Criteria (PsARC) response was greater in the secukinumab‑treated patients (59.0% and 61.0% for 150&nbsp;mg and 300&nbsp;mg, respectively) compared to placebo (26.5%) at week&nbsp;24.</p><p>&nbsp;</p><p>In PsA study&nbsp;1 and PsA study&nbsp;2, efficacy was maintained up to week&nbsp;104. In PsA study&nbsp;2, among 200&nbsp;patients initially randomised to secukinumab 150&nbsp;mg and 300&nbsp;mg, 178 (89%) patients were still on treatment at week&nbsp;52. Of the 100&nbsp;patients randomised to secukinumab 150&nbsp;mg, 64, 39 and 20 had an ACR&nbsp;20/50/70 response, respectively. Of the 100&nbsp;patients randomised to secukinumab 300&nbsp;mg, 64, 44 and 24 had an ACR&nbsp;20/50/70 response, respectively.</p><p>&nbsp;</p><p><em>Radiographic response</em></p><p>In PsA study&nbsp;3, inhibition of progression of structural damage was assessed radiographically and expressed by the modified Total Sharp Score (mTSS) and its components, the Erosion Score (ES) and the Joint Space Narrowing Score (JSN). Radiographs of hands, wrists, and feet were obtained at baseline, week&nbsp;16 and/or week&nbsp;24 and scored independently by at least two readers who were blinded to treatment group and visit number. Secukinumab 150&nbsp;mg and 300&nbsp;mg treatment significantly inhibited the rate of progression of peripheral joint damage compared with placebo treatment as measured by change from baseline in mTSS at week&nbsp;24 (Table&nbsp;10).</p><p>&nbsp;</p><p>Inhibition of progression of structural damage was also assessed in PsA study&nbsp;1 at weeks&nbsp;24 and 52, compared to baseline. Week&nbsp;24 data are presented in Table&nbsp;10.</p><p>&nbsp;</p><p><strong>Table&nbsp;10&nbsp;&nbsp;&nbsp;&nbsp; Change in modified Total Sharp Score in psoriatic arthritis</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>PsA study&nbsp;3</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PsA study&nbsp;1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>n=296</strong></p></td><td style="vertical-align:top"><p><strong>secukinumab 150&nbsp;mg<sup>1</sup></strong></p><p><strong>n=213</strong></p></td><td style="vertical-align:top"><p><strong>secukinumab 300&nbsp;mg<sup>1</sup></strong></p><p><strong>n=217</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>n=179</strong></p></td><td style="vertical-align:top"><p><strong>secukinumab 150&nbsp;mg<sup>2</sup></strong></p><p><strong>n=185</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Total score</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline</strong></p><p><strong>(SD)</strong></p></td><td style="vertical-align:top"><p>15.0</p><p>(38.2)</p></td><td style="vertical-align:top"><p>13.5</p><p>(25.6)</p></td><td style="vertical-align:top"><p>12.9</p><p>(23.8)</p></td><td style="vertical-align:top"><p>28.4</p><p>(63.5)</p></td><td style="vertical-align:top"><p>22.3</p><p>(48.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean change at week&nbsp;24</strong></p></td><td style="vertical-align:top"><p>0.50</p></td><td style="vertical-align:top"><p>0.13*</p></td><td style="vertical-align:top"><p>0.02*</p></td><td style="vertical-align:top"><p>0.57</p></td><td style="vertical-align:top"><p>0.13*</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>*p&lt;0.05 based on nominal, but non adjusted, p-value</p><p><sup>1</sup>secukinumab 150 mg or 300 mg s.c. at weeks 0, 1, 2, 3, and 4 followed by the same dose every month</p><p><sup>2</sup>10&nbsp;mg/kg at weeks&nbsp;0, 2 and 4 followed by subcutaneous doses of 75&nbsp;mg or 150&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p>In PsA study&nbsp;1, inhibition of structural damage was maintained with secukinumab treatment up to week&nbsp;52.</p><p>&nbsp;</p><p>In PsA study&nbsp;3, the percentage of patients with no disease progression (defined as a change from baseline in mTSS of &le;0.5) from randomisation to week&nbsp;24 was 80.3%, 88.5% and 73.6% for secukinumab 150&nbsp;mg, 300&nbsp;mg and placebo, respectively. An effect of inhibition of structural damage was observed in anti‑TNF&alpha;‑na&iuml;ve and anti‑TNF&alpha;‑IR patients and in patients treated with and without concomitant MTX.</p><p>&nbsp;</p><p>In PsA study&nbsp;1, the percentage of patients with no disease progression (defined as a change from baseline in mTSS of &le;0.5) from randomisation to week&nbsp;24 was 82.3% in secukinumab 10&nbsp;mg/kg intravenous load &ndash; 150&nbsp;mg subcutaneous maintenance and 75.7% in placebo. The percentage of patients with no disease progression from week&nbsp;24 to week&nbsp;52 for secukinumab 10&nbsp;mg/kg intravenous load &ndash; followed by 150&nbsp;mg subcutaneous maintenance and for placebo patients who switched to 75&nbsp;mg or 150&nbsp;mg subcutaneous every 4&nbsp;weeks at week&nbsp;16 or week&nbsp;24 was 85.7% and 86.8%, respectively.</p><p><em>Axial manifestations in PsA</em></p><p>A randomised, double-blind, placebo-controlled study (MAXIMISE) assessed the efficacy of secukinumab in 485 PsA patients with axial manifestations who were naive to biologic treatment and responded inadequately to NSAIDs. The primary variable of at least a 20% improvement in Assessment of SpondyloArthritis International Society (ASAS&nbsp;20) criteria at week&nbsp;12 was met. Treatment with secukinumab 300&nbsp;mg and 150&nbsp;mg compared to placebo also resulted in greater improvement in signs and symptoms (including decreases from baseline in spinal pain) and improvement in physical function (see Table&nbsp;11).</p><p>&nbsp;</p><p><strong>Table&nbsp;11&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Clinical response on MAXIMISE study at week&nbsp;12</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(n=164)</strong></p></td><td style="vertical-align:top"><p><strong>150&nbsp;mg</strong></p><p><strong>(n=157)</strong></p></td><td style="vertical-align:top"><p><strong>300&nbsp;mg</strong></p><p><strong>(n=164)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;20 response, %</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>31.2 (24.6, 38.7)</p></td><td style="vertical-align:top"><p>66.3 (58.4, 73.3)*</p></td><td style="vertical-align:top"><p>62.9 (55.2, 70.0)*</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;40 response, %</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>12.2 (7.8, 18.4)</p></td><td style="vertical-align:top"><p>39.5 (32.1, 47.4)**</p></td><td style="vertical-align:top"><p>43.6 (36.2, 51.3)**</p></td></tr><tr><td style="vertical-align:bottom"><p>BASDAI 50, %</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>9.8 (5.9, 15.6)</p></td><td style="vertical-align:top"><p>32.7 (25.8, 40.5)**</p></td><td style="vertical-align:top"><p>37.4 (30.1, 45.4)**</p></td></tr><tr><td style="vertical-align:top"><p>Spinal pain, VAS</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>-13.6 (-17.2, -10.0)</p></td><td style="vertical-align:top"><p>-28.5 (-32.2, -24.8)**</p></td><td style="vertical-align:top"><p>-26.5 (-30.1, -22.9)**</p></td></tr><tr><td style="vertical-align:top"><p>Physical function, HAQ‑DI</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>-0.155 (-0.224, -0.086)</p></td><td style="vertical-align:top"><p>-0.330 (-0.401,<br />-0.259)**</p></td><td style="vertical-align:top"><p>-0.389 (-0.458,<br />-0.320)**</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* p&lt;0.0001; versus placebo using multiple imputation.</p><p>** Comparison versus placebo was not adjusted for multiplicity.</p><p>ASAS:&nbsp;Assessment of SpondyloArthritis International Society Criteria; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; VAS: Visual Analog Scale; HAQ‑DI: Health Assessment Questionnaire &ndash; Disability Index.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>Improvement in ASAS&nbsp;20 and ASAS&nbsp;40 for both secukinumab doses were observed by week&nbsp;4 and were maintained up to 52&nbsp;weeks.</p><p>&nbsp;</p><p><em>Physical function and health‑related quality of life</em></p><p>In PsA study&nbsp;2 and PsA study&nbsp;3, patients treated with secukinumab 150&nbsp;mg (p=0.0555 and p&lt;0.0001) and 300&nbsp;mg (p=0.0040 and p&lt;0.0001) showed improvement in physical function compared to patients treated with placebo as assessed by Health Assessment Questionnaire‑Disability Index (HAQ‑DI) at week&nbsp;24 and week&nbsp;16, respectively. Improvements in HAQ‑DI scores were seen regardless of previous anti‑TNF&alpha; exposure. Similar responses were seen in PsA study&nbsp;1.</p><p>&nbsp;</p><p>Secukinumab‑treated patients reported significant improvements in health‑related quality of life as measured by the Short Form-36 Health Survey Physical Component Summary (SF‑36 PCS) score (p&lt;0.001). There were also statistically significant improvements demonstrated in exploratory endpoints assessed by the Functional Assessment of Chronic Illness Therapy &ndash; Fatigue (FACIT-F) scores for 150&nbsp;mg and 300&nbsp;mg compared to placebo (7.97, 5.97 versus 1.63, respectively) and these improvements were maintained up to week&nbsp;104 in PsA study&nbsp;2.</p><p>&nbsp;</p><p>Similar responses were seen in PsA study&nbsp;1 and efficacy was maintained up to week&nbsp;52.</p><p><em><u>Axial spondyloarthritis (axSpA)</u></em></p><p><em>Ankylosing spondylitis (AS) / Radiographic axial spondyloarthritis</em></p><p>The safety and efficacy of secukinumab were assessed in 816&nbsp;patients in three randomised, double‑blind, placebo‑controlled phase III studies in patients with active ankylosing spondylitis (AS) with a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &ge;4 despite non‑steroidal anti‑inflammatory drug (NSAID), corticosteroid or disease‑modifying anti‑rheumatic drug (DMARD) therapy. Patients in Ankylosing Spondylitis study&nbsp;1 (AS study&nbsp;1) and Ankylosing Spondylitis study&nbsp;2 (AS study&nbsp;2) had a diagnosis of AS for a median of 2.7 to 5.8&nbsp;years. For both studies, the primary endpoint was at least a 20% improvement in Assessment of SpondyloArthritis International Society (ASAS&nbsp;20) criteria at week&nbsp;16.</p><p>&nbsp;</p><p>In Ankylosing Spondylitis study&nbsp;1 (AS study&nbsp;1), Ankylosing Spondylitis study&nbsp;2 (AS study&nbsp;2), and Ankylosing Spondylitis study&nbsp;3 (AS study&nbsp;3), 27.0%, 38.8%, and 23.5% of patients, respectively, were previously treated with an anti‑TNF&alpha; agent and discontinued the anti-TNF&alpha; agent for either lack of efficacy or intolerance (anti-TNF&alpha;-IR patients).</p><p>&nbsp;</p><p>AS study&nbsp;1 (MEASURE&nbsp;1) evaluated 371&nbsp;patients, of whom 14.8% and 33.4% used concomitant MTX or sulfasalazine, respectively. Patients randomised to secukinumab received 10&nbsp;mg/kg intravenously at weeks&nbsp;0, 2, and 4, followed by either 75&nbsp;mg or 150&nbsp;mg subcutaneously every month starting at week&nbsp;8. Patients randomised to placebo who were non‑responders at week&nbsp;16 (early rescue) and all other placebo patients at week&nbsp;24 were crossed over to receive secukinumab (either 75&nbsp;mg or 150&nbsp;mg subcutaneously), followed by the same dose every month.</p><p>&nbsp;</p><p>AS study&nbsp;2 (MEASURE&nbsp;2) evaluated 219&nbsp;patients, of whom 11.9% and 14.2% used concomitant MTX or sulfasalazine, respectively. Patients randomised to secukinumab received 75&nbsp;mg or 150&nbsp;mg subcutaneously at weeks&nbsp;0, 1, 2, 3 and 4, followed by the same dose every month. At week&nbsp;16, patients who were randomised to placebo at baseline were re‑randomised to receive secukinumab (either 75&nbsp;mg or 150&nbsp;mg subcutaneously) every month.</p><p>&nbsp;</p><p>AS study&nbsp;3 (MEASURE&nbsp;3) evaluated 226&nbsp;patients, of whom 13.3% and 23.5% used concomitant MTX or sulfasalazine, respectively. Patients randomised to secukinumab received 10&nbsp;mg/kg intravenously at weeks&nbsp;0, 2, and 4, followed by either 150&nbsp;mg or 300&nbsp;mg subcutaneously every month. At week&nbsp;16, patients who were randomised to placebo at baseline were re-randomised to receive secukinumab (either 150&nbsp;mg or 300&nbsp;mg subcutaneously) every month. The primary endpoint was ASAS&nbsp;20 at week&nbsp;16. Patients were blinded to the treatment regimen up to week&nbsp;52, and the study continued to week&nbsp;156.</p><p>&nbsp;</p><p>Signs and symptoms:</p><p>In AS study&nbsp;2, treatment with secukinumab 150&nbsp;mg resulted in greater improvement in measures of disease activity compared with placebo at week&nbsp;16 (see Table&nbsp;12).</p><p><strong>Table&nbsp;</strong><strong>12</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical response in AS study&nbsp;2 at week&nbsp;16</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:613px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Outcome (p-value versus placebo)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(n = 74)</strong></p></td><td style="vertical-align:bottom"><p><strong>75&nbsp;mg</strong></p><p><strong>(n = 73)</strong></p></td><td style="vertical-align:bottom"><p><strong>150&nbsp;mg</strong></p><p><strong>(n = 72)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;20 response, %</p></td><td style="vertical-align:bottom"><p>28.4</p></td><td style="vertical-align:bottom"><p>41.1</p></td><td style="vertical-align:bottom"><p>61.1***</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;40 response, %</p></td><td style="vertical-align:bottom"><p>10.8</p></td><td style="vertical-align:bottom"><p>26.0</p></td><td style="vertical-align:bottom"><p>36.1***</p></td></tr><tr><td style="vertical-align:bottom"><p>hsCRP, (post‑BSL/BSL ratio)</p></td><td style="vertical-align:bottom"><p>1.13</p></td><td style="vertical-align:bottom"><p>0.61</p></td><td style="vertical-align:bottom"><p>0.55***</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS&nbsp;5/6, %</p></td><td style="vertical-align:bottom"><p>8.1</p></td><td style="vertical-align:bottom"><p>34.2</p></td><td style="vertical-align:bottom"><p>43.1***</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS partial remission, %</p></td><td style="vertical-align:bottom"><p>4.1</p></td><td style="vertical-align:bottom"><p>15.1</p></td><td style="vertical-align:bottom"><p>13.9</p></td></tr><tr><td style="vertical-align:bottom"><p>BASDAI&nbsp;50, %</p></td><td style="vertical-align:bottom"><p>10.8</p></td><td style="vertical-align:bottom"><p>24.7*</p></td><td style="vertical-align:bottom"><p>30.6**</p></td></tr><tr><td style="vertical-align:bottom"><p>ASDAS-CRP major improvement</p></td><td style="vertical-align:bottom"><p>4.1</p></td><td style="vertical-align:bottom"><p>15.1*</p></td><td style="vertical-align:bottom"><p>25.0***</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001; versus placebo</p><p>All p-values adjusted for multiplicity of testing based on pre‑defined hierarchy, except BASDAI 50 and ASDAS-CRP</p><p>Non‑responder imputation used for missing binary endpoint</p><p>&nbsp;</p><p>ASAS:&nbsp;Assessment of SpondyloArthritis International Society Criteria; BASDAI:&nbsp;Bath Ankylosing Spondylitis Disease Activity Index; hsCRP:&nbsp;high‑sensitivity C‑reactive protein; ASDAS: Ankylosing Spondylitis Disease Activity Score; BSL:&nbsp;baseline</p></td></tr></tbody></table><p>&nbsp;</p><p>The onset of action of secukinumab 150&nbsp;mg occurred as early as week&nbsp;1 for ASAS&nbsp;20 and week&nbsp;2 for ASAS&nbsp;40 (superior to placebo) in AS study&nbsp;2.</p><p>&nbsp;</p><p>ASAS&nbsp;20 responses were improved at week&nbsp;16 in both anti‑TNF&alpha;-na&iuml;ve patients (68.2% versus 31.1%; p&lt;0.05) and anti‑TNF&alpha;‑IR patients (50.0% versus 24.1%; p&lt;0.05) for secukinumab 150&nbsp;mg compared with placebo, respectively.</p><p>&nbsp;</p><p>In AS study&nbsp;1 and AS study&nbsp;2, secukinumab‑treated patients (150&nbsp;mg in AS study&nbsp;2 and both regimens in AS study&nbsp;1) demonstrated significantly improved signs and symptoms at week&nbsp;16, with comparable magnitude of response and efficacy maintained up to week&nbsp;52 in both anti‑TNF&alpha;‑naive and anti‑TNF&alpha;‑IR patients. In AS study&nbsp;2, among 72&nbsp;patients initially randomised to secukinumab 150&nbsp;mg, 61&nbsp;(84.7%) patients were still on treatment at week&nbsp;52. Of the 72&nbsp;patients randomised to secukinumab 150&nbsp;mg, 45 and 35 had an ASAS&nbsp;20/40 response, respectively.</p><p>&nbsp;</p><p>In AS study&nbsp;3, patients treated with secukinumab (150&nbsp;mg and 300&nbsp;mg) demonstrated improved signs and symptoms, and had comparable efficacy responses regardless of dose that were superior to placebo at week&nbsp;16 for the primary endpoint (ASAS&nbsp;20). Overall, the efficacy response rates for the 300&nbsp;mg group were consistently greater compared to the 150&nbsp;mg group for the secondary endpoints. During the blinded period, the ASAS&nbsp;20 and ASAS&nbsp;40 responses were 69.7% and 47.6% for 150&nbsp;mg and 74.3% and 57.4% for 300&nbsp;mg at week&nbsp;52, respectively. The ASAS&nbsp;20 and ASAS&nbsp;40 responses were maintained up to week&nbsp;156 (69.5% and 47.6% for 150&nbsp;mg versus 74.8% and 55.6% for 300&nbsp;mg). Greater response rates favouring 300&nbsp;mg were also observed for ASAS partial remission (ASAS PR) response at week&nbsp;16 and were maintained up to week&nbsp;156. Larger differences in response rates, favouring 300&nbsp;mg over 150&nbsp;mg, were observed in anti‑TNF&alpha;‑IR patients (n=36) compared to anti‑TNF&alpha;-na&iuml;ve patients (n=114).</p><p>Spinal mobility:</p><p>Patients treated with secukinumab 150&nbsp;mg showed improvements in spinal mobility as measured by change from baseline in BASMI at week&nbsp;16 for both AS study&nbsp;1 (‑0.40 versus ‑0.12 for placebo; p=0.0114) and AS study&nbsp;2 (‑0.51 versus ‑0.22 for placebo; p=0.0533). These improvements were sustained up to week&nbsp;52.</p><p>&nbsp;</p><p>Physical function and health‑related quality of life:</p><p>In AS study&nbsp;1 and study&nbsp;2, patients treated with secukinumab 150&nbsp;mg showed improvements in health-related quality of life as measured by AS Quality of Life Questionnaire (ASQoL) (p=0.001) and SF-36 Physical Component Summary (SF-36PCS) (p&lt;0.001). Patients treated with secukinumab 150&nbsp;mg also showed statistically significant improvements on exploratory endpoints in physical function as assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI) compared to placebo (‑2.15 versus ‑0.68), and in fatigue as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale compared to placebo (8.10 versus 3.30). These improvements were sustained up to week&nbsp;52.</p><p>&nbsp;</p><p><em>Non-radiographic axial spondyloarthritis (nr-axSpA)</em></p><p>The safety and efficacy of secukinumab were assessed in 555&nbsp;patients in one randomised, double‑blind, placebo-controlled phase III study (PREVENT), consisting of a 2-year core phase and a 2-year extension phase, in patients with active non-radiographic axial spondyloarthritis (nr‑axSpA) fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis (axSpA) with no radiographic evidence of changes in the sacroiliac joints that would meet the modified New York criteria for ankylosing spondylitis (AS). Patients enrolled had active disease, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &ge;4, a Visual Analogue Scale (VAS) for total back pain of &ge;40 (on a scale of 0-100&nbsp;mm), despite current or previous non-steroidal anti-inflammatory drug (NSAID) therapy and increased C‑reactive protein (CRP) and/or evidence of sacroiliitis on Magnetic Resonance Imaging (MRI). Patients in this study had a diagnosis of axSpA for a mean of 2.1 to 3.0&nbsp;years and 54% of the study participants were female.</p><p>&nbsp;</p><p>In the PREVENT study, 9.7% of patients were previously treated with an anti-TNF&alpha; agent and discontinued the anti-TNF&alpha; agent for either lack of efficacy or intolerance (anti-TNF&alpha;-IR patients).</p><p>&nbsp;</p><p>In the PREVENT study, 9.9% and 14.8% of patients used concomitant MTX or sulfasalazine, respectively. In the double-blind period, patients received either placebo or secukinumab for 52&nbsp;weeks. Patients randomised to secukinumab received 150&nbsp;mg subcutaneously at weeks&nbsp;0, 1, 2, 3 and 4 followed by the same dose every month, or a once monthly injection of secukinumab 150&nbsp;mg. The primary endpoint was at least 40% improvement in Assessment of SpondyloArthritis International Society (ASAS 40) at Week&nbsp;16 in anti‑TNF&alpha;-naive patients.</p><p>&nbsp;</p><p>Signs and symptoms:</p><p>In the PREVENT study, treatment with secukinumab 150&nbsp;mg resulted in significant improvements in the measures of disease activity compared to placebo at week&nbsp;16. These measures include ASAS 40, ASAS 5/6, BASDAI score, BASDAI 50, high-sensitivity CRP (hsCRP), ASAS 20 and ASAS partial remission response compared to placebo (Table&nbsp;13). Responses were maintained up to week&nbsp;52.</p><p><strong>Table&nbsp;13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical response in the PREVENT study at week&nbsp;16</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><thead><tr><td style="vertical-align:bottom"><p><strong>Outcome (p-value versus placebo)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>150&nbsp;mg<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Number of anti-TNF&alpha;-naive patients randomised</strong></p></td><td style="vertical-align:top"><p><strong>171</strong></p></td><td style="vertical-align:top"><p><strong>164</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS 40 response, %</p></td><td style="vertical-align:top"><p>29.2</p></td><td style="vertical-align:top"><p>41.5*</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Total number of patients randomised</strong></p></td><td style="vertical-align:top"><p><strong>186</strong></p></td><td style="vertical-align:top"><p><strong>185</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS 40 response, %</p></td><td style="vertical-align:top"><p>28.0</p></td><td style="vertical-align:top"><p>40.0*</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS 5/6, %</p></td><td style="vertical-align:top"><p>23.7</p></td><td style="vertical-align:top"><p>40.0*</p></td></tr><tr><td style="vertical-align:bottom"><p>BASDAI, LS mean change from baseline score</p></td><td style="vertical-align:top"><p>-1.46</p></td><td style="vertical-align:top"><p>-2.35*</p></td></tr><tr><td style="vertical-align:bottom"><p>BASDAI 50, %</p></td><td style="vertical-align:top"><p>21.0</p></td><td style="vertical-align:top"><p>37.3*</p></td></tr><tr><td style="vertical-align:bottom"><p>hsCRP, (post-BSL/BSL ratio)</p></td><td style="vertical-align:top"><p>0.91</p></td><td style="vertical-align:top"><p>0.64*</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS 20 response, %</p></td><td style="vertical-align:top"><p>45.7</p></td><td style="vertical-align:top"><p>56.8*</p></td></tr><tr><td style="vertical-align:bottom"><p>ASAS partial remission, %</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>21.6*</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>*p&lt;0.05 versus placebo</p><p>All p-values adjusted for multiplicity of testing based on pre-defined hierarchy</p><p>Non-responder imputation used for missing binary endpoint</p><p><sup>1</sup>secukinumab 150&nbsp;mg s.c. at weeks 0, 1, 2, 3, and 4 followed by the same dose every month</p><p>&nbsp;</p><p>ASAS: Assessment of SpondyloArthritis International Society Criteria; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; hsCRP: high-sensitivity C-reactive protein; BSL: baseline; LS: Least square</p></td></tr></thead></table><p>&nbsp;</p><p>The onset of action of secukinumab 150&nbsp;mg occurred as early as week&nbsp;3 for ASAS 40 in anti-TNF&alpha; naive patients (superior to placebo) in the PREVENT study. The percentage of patients achieving an ASAS 40 response in anti-TNF&alpha; naive patients by visit is shown in Figure&nbsp;3.</p><p><strong>Figure&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASAS 40 responses in anti-TNF&alpha; naive patients in the PREVENT study over time up to week&nbsp;16</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="802" height="389" vspace="0" hspace="0" border="0" style="width:802px;height:389px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>ASAS 40 responses were also improved at week&nbsp;16 in anti-TNF&alpha;-IR patients for secukinumab 150&nbsp;mg compared with placebo.</p><p>&nbsp;</p><p>Physical function and health‑related quality of life:</p><p>Patients treated with secukinumab 150&nbsp;mg showed statistically significant improvements by week&nbsp;16 compared to placebo-treated patients in physical function as assessed by the BASFI (week&nbsp;16: -1.75 versus -1.01, p&lt;0.05). Patients treated with secukinumab reported significant improvements compared to placebo-treated patients by week&nbsp;16 in health-related quality of life as measured by ASQoL (LS mean change: week&nbsp;16: -3.45 versus -1.84, p&lt;0.05) and SF-36 Physical Component Summary (SF-36 PCS) (LS mean change: week&nbsp;16: 5.71 versus 2.93, p&lt;0.05). These improvements were sustained up to week&nbsp;52.</p><p>&nbsp;</p><p>Spinal mobility:</p><p>Spinal mobility was assessed by BASMI up to week&nbsp;16. Numerically greater improvements were demonstrated in patients treated with secukinumab compared with placebo-treated patients at weeks&nbsp;4, 8, 12 and 16.</p><p>&nbsp;</p><p>Inhibition of inflammation in magnetic resonance imaging (MRI):</p><p>Signs of inflammation were assessed by MRI at baseline and week&nbsp;16 and expressed as change from baseline in Berlin SI-joint oedema score for sacroiliac joints and ASspiMRI-a score and Berlin spine score for the spine. Inhibition of inflammatory signs in both sacroiliac joints and the spine was observed in patients treated with secukinumab. Mean change from baseline in Berlin SI-joint oedema score was -1.68 for patients treated with secukinumab 150&nbsp;mg (n=180) versus -0.39 for the placebo‑treated patients (n=174) (p&lt;0.05).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em><u>Paediatric plaque psoriasis</u></em></p><p>Secukinumab has been shown to improve signs and symptoms, and health‑related quality of life in paediatric patients 6&nbsp;years and older with plaque psoriasis (see Tables&nbsp;15 and 17).</p><p>&nbsp;</p><p><em>Severe plaque psoriasis</em></p><p>The safety and efficacy of secukinumab were assessed in a randomised, double-blind, placebo and etanercept-controlled phase&nbsp;III study in paediatric patients from 6 to &lt;18&nbsp;years of age with severe plaque psoriasis, as defined by a PASI score &ge;20, an IGA mod 2011 score of 4, and BSA involvement of &ge;10%, who were candidates for systemic therapy. Approximately 43% of the patients had prior exposure to phototherapy, 53% to conventional systemic therapy, 3% to biologics, and 9% had concomitant psoriatic arthritis.</p><p>&nbsp;</p><p>The paediatric psoriasis study&nbsp;1 evaluated 162&nbsp;patients who were randomised to receive low dose secukinumab (75&nbsp;mg for body weight &lt;50&nbsp;kg or 150&nbsp;mg for body weight &ge;50&nbsp;kg), high dose secukinumab (75&nbsp;mg for body weight &lt;25&nbsp;kg, 150&nbsp;mg for body weight between &ge;25&nbsp;kg and &lt;50&nbsp;kg, or 300&nbsp;mg for body weight &ge;50&nbsp;kg), or placebo at weeks&nbsp;0, 1, 2, 3, and 4 followed by the same dose every 4&nbsp;weeks, or etanercept. Patients randomised to etanercept received 0.8&nbsp;mg/kg weekly (up to a maximum of 50&nbsp;mg). Patient distribution by weight and age at randomisation is described in Table&nbsp;14.</p><p>&nbsp;</p><p><strong>Table&nbsp;14&nbsp;&nbsp;&nbsp;&nbsp; Patient distribution by weight</strong><strong> </strong><strong>and age for </strong><strong>paediatric psoriasis study&nbsp;1</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>Randomisation strata</strong></p></td><td style="vertical-align:top"><p><strong>Description</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>low dose</strong></p><p><strong>n=40</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>high dose</strong></p><p><strong>n=40</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=41</strong></p></td><td style="vertical-align:top"><p><strong>Etanercept</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=41</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=162</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p>6-&lt;12&nbsp;years</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>37</p></td></tr><tr><td style="vertical-align:top"><p>&ge;12-&lt;18&nbsp;years</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>125</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>&lt;25&nbsp;kg</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>&ge;25-&lt;50&nbsp;kg</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>65</p></td></tr><tr><td style="vertical-align:top"><p>&ge;50&nbsp;kg</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>85</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients randomised to receive placebo who were non-responders at week&nbsp;12 were switched to either the secukinumab low or high dose group (dose based on body weight group) and received study drug at weeks&nbsp;12, 13, 14, and 15, followed by the same dose every 4&nbsp;weeks starting at week&nbsp;16. The co-primary endpoints were the proportion of patients who achieved a PASI 75 response and IGA mod 2011 &lsquo;clear&rsquo; or &lsquo;almost clear&rsquo; (0 or 1) response at week&nbsp;12.</p><p>&nbsp;</p><p>During the 12&nbsp;week placebo-controlled period, the efficacy of both the low and the high dose of secukinumab was comparable for the co-primary endpoints. The odds ratio estimates in favour of both secukinumab doses were statistically significant for both the PASI 75 and IGA mod 2011 0 or 1 responses.</p><p>&nbsp;</p><p>All patients were followed for efficacy and safety during the 52&nbsp;weeks following the first dose. The proportion of patients achieving PASI 75 and IGA mod 2011 &lsquo;clear&rsquo; or &lsquo;almost clear&rsquo; (0 or 1) responses showed separation between secukinumab treatment groups and placebo at the first post-baseline visit at week&nbsp;4, the difference becoming more prominent at week&nbsp;12. The response was maintained throughout the 52&nbsp;week time period (see Table&nbsp;15). Improvement in PASI 50, 90, 100 responder rates and Children&rsquo;s Dermatology Life Quality Index (CDLQI) scores of 0 or 1 were also maintained throughout the 52&nbsp;week time period.</p><p>&nbsp;</p><p>In addition, PASI 75, IGA 0 or 1, PASI 90 response rates at weeks&nbsp;12 and 52 for both secukinumab low and high dose groups were higher than the rates for patients treated with etanercept (see Table&nbsp;15).</p><p>Beyond week&nbsp;12, efficacy of both the low and the high dose of secukinumab was comparable although the efficacy of the high dose was higher for patients &ge;50&nbsp;kg. The safety profiles of the low dose and the high dose were comparable and consistent with the safety profile in adults.</p><p>&nbsp;</p><p><strong>Table&nbsp;15&nbsp;&nbsp;&nbsp;&nbsp; Summary of clinical response in severe paediatric psoriasis at weeks&nbsp;12 and 52 (</strong><strong>paediatric psoriasis study&nbsp;1)*</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:101%"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Response criterion</strong></p></td><td style="vertical-align:bottom"><p><strong>Treatment comparison</strong></p></td><td style="vertical-align:bottom"><p><strong>&#39;test&#39;</strong></p></td><td style="vertical-align:bottom"><p><strong>&#39;control&#39;</strong></p></td><td style="vertical-align:bottom"><p><strong>odds ratio</strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&#39;test&#39; vs. &#39;control&#39;</strong></p></td><td style="vertical-align:bottom"><p><strong>n**/m (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>n**/m (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>estimate (95% CI)</strong></p></td><td style="vertical-align:bottom"><p><strong>p-value</strong></p></td></tr><tr><td colspan="6" style="vertical-align:bottom"><p><strong>At week&nbsp;12***</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 75</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. placebo</p></td><td style="vertical-align:top"><p>32/40 (80.0)</p></td><td style="vertical-align:top"><p>6/41 (14.6)</p></td><td style="vertical-align:top"><p>25.78 (7.08, 114.66)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>secukinumab high dose vs. placebo</p></td><td style="vertical-align:top"><p>31/40 (77.5)</p></td><td style="vertical-align:top"><p>6/41 (14.6)</p></td><td style="vertical-align:top"><p>22.65 (6.31, 98.93)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. etanercept</p></td><td style="vertical-align:top"><p>32/40 (80.0)</p></td><td style="vertical-align:top"><p>26/41 (63.4)</p></td><td style="vertical-align:top"><p>2.25 (0.73, 7.38)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>secukinumab high dose vs. etanercept</p></td><td style="vertical-align:top"><p>31/40 (77.5)</p></td><td style="vertical-align:top"><p>26/41 (63.4)</p></td><td style="vertical-align:top"><p>1.92 (0.64, 6.07)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>IGA 0/1</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. placebo</p></td><td style="vertical-align:top"><p>28/40 (70.0)</p></td><td style="vertical-align:top"><p>2/41 (4.9)</p></td><td style="vertical-align:top"><p>51.77 (10.02, 538.64)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>secukinumab high dose vs. placebo</p></td><td style="vertical-align:top"><p>24/40 (60.0)</p></td><td style="vertical-align:top"><p>2/41 (4.9)</p></td><td style="vertical-align:top"><p>32.52 (6.48, 329.52)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. etanercept</p></td><td style="vertical-align:top"><p>28/40 (70.0)</p></td><td style="vertical-align:top"><p>14/41 (34.1)</p></td><td style="vertical-align:top"><p>4.49 (1.60, 13.42)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>secukinumab high dose vs. etanercept</p></td><td style="vertical-align:top"><p>24/40 (60.0)</p></td><td style="vertical-align:top"><p>14/41 (34.1)</p></td><td style="vertical-align:top"><p>2.86 (1.05, 8.13)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 90</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. placebo</p></td><td style="vertical-align:top"><p>29/40 (72.5)</p></td><td style="vertical-align:top"><p>1/41 (2.4)</p></td><td style="vertical-align:top"><p>133.67 (16.83, 6395.22)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>secukinumab high dose vs. placebo</p></td><td style="vertical-align:top"><p>27/40 (67.5)</p></td><td style="vertical-align:top"><p>1/41 (2.4)</p></td><td style="vertical-align:top"><p>102.86 (13.22, 4850.13)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>secukinumab low dose vs. etanercept</p></td><td style="vertical-align:top"><p>29/40 (72.5)</p></td><td style="vertical-align:top"><p>12/41 (29.3)</p></td><td style="vertical-align:top"><p>7.03 (2.34, 23.19)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>secukinumab high dose vs. etanercept</p></td><td style="vertical-align:top"><p>27/40 (67.5)</p></td><td style="vertical-align:top"><p>12/41 (29.3)</p></td><td style="vertical-align:top"><p>5.32 (1.82, 16.75)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>At week&nbsp;52</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>PASI 75</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. etanercept</p></td><td style="vertical-align:top"><p>35/40 (87.5)</p></td><td style="vertical-align:top"><p>28/41 (68.3)</p></td><td style="vertical-align:top"><p>3.12 (0.91, 12.52)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>secukinumab high dose vs. etanercept</p></td><td style="vertical-align:top"><p>35/40 (87.5)</p></td><td style="vertical-align:top"><p>28/41 (68.3)</p></td><td style="vertical-align:top"><p>3.09 (0.90, 12.39)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>IGA 0/1</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. etanercept</p></td><td style="vertical-align:top"><p>29/40 (72.5)</p></td><td style="vertical-align:top"><p>23/41 (56.1)</p></td><td style="vertical-align:top"><p>2.02 (0.73, 5.77)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>secukinumab high dose vs. etanercept</p></td><td style="vertical-align:top"><p>30/40 (75.0)</p></td><td style="vertical-align:top"><p>23/41 (56.1)</p></td><td style="vertical-align:top"><p>2.26 (0.81, 6.62)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>PASI 90</strong></p></td><td style="vertical-align:top"><p>secukinumab low dose vs. etanercept</p></td><td style="vertical-align:top"><p>30/40 (75.0)</p></td><td style="vertical-align:top"><p>21/41 (51.2)</p></td><td style="vertical-align:top"><p>2.85 (1.02, 8.38)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>secukinumab high dose vs. etanercept</p></td><td style="vertical-align:top"><p>32/40 (80.0)</p></td><td style="vertical-align:top"><p>21/41 (51.2)</p></td><td style="vertical-align:top"><p>3.69 (1.27, 11.61)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>*&nbsp; non-responder imputation was used to handle missing values</p><p>** n is the number of responders, m = number of patients evaluable</p><p>*** extended visit window at week&nbsp;12</p><p>Odds ratio, 95% confidence interval, and p-value are from an exact logistic regression model with treatment group, baseline body-weight category and age category as factors</p></td></tr></tbody></table><p>&nbsp;</p><p>A higher proportion of paediatric patients treated with secukinumab reported improvement in health-related quality of life as measured by a CDLQI score of 0 or 1 compared to placebo at week&nbsp;12 (low dose 44.7%, high dose 50%, placebo 15%). Over time up to and including week&nbsp;52 both secukinumab dose groups were numerically higher than the etanercept group (low dose 60.6%, high dose 66.7%, etanercept 44.4%).</p><p>&nbsp;</p><p><em>Moderate to severe plaque psoriasis</em></p><p>Secukinumab was predicted to be effective for the treatment of paediatric patients with moderate plaque psoriasis based on the demonstrated efficacy and exposure response relationship in adult patients with moderate to severe plaque psoriasis, and the similarity of the disease course, pathophysiology, and drug effect in adult and paediatric patients at the same exposure levels.</p><p>&nbsp;</p><p>Moreover, the safety and efficacy of secukinumab was assessed in an open‑label, two-arm, parallel‑group, multicentre phase&nbsp;III study in paediatric patients from 6 to &lt;18&nbsp;years of age with moderate to severe plaque psoriasis, as defined by a PASI score &ge;12, an IGA mod 2011 score of &ge;3, and BSA involvement of &ge;10%, who were candidates for systemic therapy.</p><p>The paediatric psoriasis study&nbsp;2 evaluated 84&nbsp;patients who were randomised to receive low dose secukinumab (75&nbsp;mg for body weight &lt;50&nbsp;kg or 150&nbsp;mg for body weight &ge;50&nbsp;kg) or high dose secukinumab (75&nbsp;mg for body weight &lt;25&nbsp;kg, 150&nbsp;mg for body weight between &ge;25&nbsp;kg and &lt;50&nbsp;kg, or 300&nbsp;mg for body weight &ge;50&nbsp;kg) at weeks&nbsp;0, 1, 2, 3, and 4 followed by the same dose every 4&nbsp;weeks. Patient distribution by weight and age at randomisation is described in Table&nbsp;16.</p><p>&nbsp;</p><p><strong>Table&nbsp;16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient distribution by weight</strong><strong> </strong><strong>and age for </strong><strong>paediatric psoriasis study&nbsp;2</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>Sub-groups</strong></p></td><td style="vertical-align:top"><p><strong>Description</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>low dose</strong></p><p><strong>n=42</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>high dose</strong></p><p><strong>n=42</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=84</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p>6-&lt;12&nbsp;years</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p>&ge;12-&lt;18&nbsp;years</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>51</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>&lt;25&nbsp;kg</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>&ge;25-&lt;50&nbsp;kg</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p>&ge;50&nbsp;kg</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>51</p></td></tr></tbody></table><p>&nbsp;</p><p>The co-primary endpoints were the proportion of patients who achieved a PASI 75 response and IGA mod 2011 &lsquo;clear&rsquo; or &lsquo;almost clear&rsquo; (0 or 1) response at week&nbsp;12.</p><p>&nbsp;</p><p>The efficacy of both the low and the high dose of secukinumab was comparable and showed statistically significant improvement compared to historical placebo for the co-primary endpoints. The estimated posterior probability of a positive treatment effect was 100%.</p><p>&nbsp;</p><p>Patients were followed for efficacy over a 52&nbsp;week period after first administration. Efficacy (defined as PASI 75 response and IGA mod 2011 &lsquo;clear&rsquo; or &lsquo;almost clear&rsquo; [0 or 1]) was observed as early as the first post-baseline visit at week&nbsp;2, and the proportion of patients who achieved a PASI 75 response and IGA mod 2011 &lsquo;clear&rsquo; or &lsquo;almost clear&rsquo; (0 or 1) increased up to week&nbsp;24 and were sustained until week&nbsp;52. Improvement in PASI 90 and PASI 100 were also observed at week&nbsp;12, increased up to week&nbsp;24, and were sustained until week&nbsp;52 (see Table&nbsp;17).</p><p>&nbsp;</p><p>The safety profiles of the low dose and the high dose were comparable and consistent with the safety profile in adults.</p><p>&nbsp;</p><p><strong>Table&nbsp;17&nbsp;&nbsp;&nbsp;&nbsp; Summary of clinical response in moderate to severe paediatric psoriasis at weeks&nbsp;12 and 52 (</strong><strong>paediatric psoriasis study&nbsp;2)*</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week&nbsp;12</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week&nbsp;52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>low dose</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>high dose</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>low dose</strong></p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p><strong>high dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>42</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>39 (92.9%)</p></td><td style="vertical-align:top"><p>39 (92.9%)</p></td><td style="vertical-align:top"><p>37 (88.1%)</p></td><td style="vertical-align:top"><p>38 (90.5%)</p></td></tr><tr><td style="vertical-align:top"><p>IGA mod 2011 &lsquo;clear&rsquo; or &lsquo;almost clear&rsquo; response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>33 (78.6%)</p></td><td style="vertical-align:top"><p>35 (83.3%)</p></td><td style="vertical-align:top"><p>36 (85.7%)</p></td><td style="vertical-align:top"><p>35 (83.3%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 90 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>29 (69%)</p></td><td style="vertical-align:top"><p>32 (76.2%)</p></td><td style="vertical-align:top"><p>32 (76.2%)</p></td><td style="vertical-align:top"><p>35 (83.3%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 100 response n&nbsp;(%)</p></td><td style="vertical-align:top"><p>25 (59.5%)</p></td><td style="vertical-align:top"><p>23 (54.8%)</p></td><td style="vertical-align:top"><p>22 (52.4%)</p></td><td style="vertical-align:top"><p>29 (69.0%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* non-responder imputation was used to handle missing values</p></td></tr></tbody></table><p>&nbsp;</p><p>These outcomes in the paediatric moderate to severe plaque psoriasis population confirmed the predictive assumptions based on the efficacy and exposure response relationship in adult patients, mentioned above.</p><p>In the low dose group, 50% and 70.7% of patients achieved a CDLQI 0 or 1 score at weeks&nbsp;12 and 52, respectively. In the high dose group, 61.9% and 70.3% achieved a CDLQI 0 or 1 score at weeks&nbsp;12 and 52, respectively.</p><p>&nbsp;</p><p><em><u>Juvenile idiopathic arthritis (JIA)</u></em></p><p><em>&nbsp;</em></p><p><em>Enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA)</em></p><p>The efficacy and safety of secukinumab were assessed in 86&nbsp;patients in a 3-part, double-blind, placebo-controlled, event-driven, randomised, phase&nbsp;III study in patients 2 to &lt;18&nbsp;years of age with active ERA or JPsA as diagnosed based on a modified International League of Associations for Rheumatology (ILAR) JIA classification criteria. The study consisted of an open-label portion (Part&nbsp;1) where all patients received secukinumab until week&nbsp;12. Patients demonstrating a JIA ACR 30 response at week&nbsp;12 entered into the Part&nbsp;2 double-blind phase and were randomised 1:1 to continue treatment with secukinumab or to begin treatment with placebo (randomised withdrawal) until week&nbsp;104 or until a flare occured. Patients who flared then entered open-label secukinumab treatment until week&nbsp;104 (Part&nbsp;3).</p><p>&nbsp;</p><p>The JIA patient subtypes at study entry were: 60.5% ERA and 39.5% JPsA, who either had inadequate response or were intolerant to &ge;1 disease-modifying antirheumatic drugs (DMARDs) and &ge;1 non-steroidal anti-inflammatory drugs (NSAIDs). At baseline, MTX use was reported for 65.1% of patients; (63.5% [33/52] of ERA patients and 67.6% [23/34] of JPsA patients). There were 12 out of 52 ERA patients concomitantly treated with sulfasalazine (23.1%). Patients with a body weight at baseline &lt;50&nbsp;kg (n=30) were given a dose of 75&nbsp;mg and patients with a body weight &ge;50&nbsp;kg (n=56) were given a dose of 150&nbsp;mg. Age at baseline ranged from 2 to 17&nbsp;years, with 3&nbsp;patients between 2 to &lt;6&nbsp;years, 22&nbsp;patients 6 to &lt;12&nbsp;years and 61&nbsp;patients 12 to &lt;18&nbsp;years. At baseline the Juvenile Arthritis Disease Activity Score (JADAS)-27 was 15.1 (SD:7.1).</p><p>&nbsp;</p><p>The primary endpoint was time to flare in the randomised withdrawal period (Part&nbsp;2). Disease flare was defined as a &ge;30% worsening in at least three of the six JIA ACR response criteria and &ge;30% improvement in not more than one of the six JIA ACR response criteria and a minimum of two active joints.</p><p>&nbsp;</p><p>At the end of Part&nbsp;1, 75 out of 86 (87.2%) patients demonstrated a JIA ACR 30 response and entered into Part&nbsp;2.</p><p>&nbsp;</p><p>The study met its primary endpoint by demonstrating a statistically significant prolongation in the time to disease flare in patients treated with secukinumab compared to placebo in Part&nbsp;2. The risk of flare was reduced by 72% for patients on secukinumab compared with patients on placebo in Part&nbsp;2 (Hazard ratio=0.28, 95% CI: 0.13 to 0.63, p&lt;0.001) (Figure&nbsp;4 and Table&nbsp;18). During Part&nbsp;2, a total of 21&nbsp;patients in the placebo group experienced a flare event (11 JPsA and 10 ERA) compared with 10&nbsp;patients in the secukinumab group (4 JPsA and 6 ERA).</p><p><strong>Figure&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier estimates of the time to disease flare in Part&nbsp;2</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="766" height="304" vspace="0" hspace="0" border="0" style="width:766px;height:304px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;18&nbsp;&nbsp;&nbsp;&nbsp; Survival analysis of time to disease flare &ndash; Part&nbsp;2</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Secukinumab</strong></p><p>(N=37)</p></td><td style="vertical-align:top"><p><strong>Placebo in Part&nbsp;2</strong></p><p>(N=38)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of flare events at the end of Part&nbsp;2, n (%)</strong></p></td><td style="vertical-align:top"><p>10 (27.0)</p></td><td style="vertical-align:top"><p>21 (55.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kaplan-Meier estimates:</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median, in days (95% CI)</p></td><td style="vertical-align:top"><p>NC (NC, NC)</p></td><td style="vertical-align:top"><p>453.0 (114.0, NC)</p></td></tr><tr><td style="vertical-align:top"><p>Flare-free rate at 6&nbsp;months (95% CI)</p></td><td style="vertical-align:top"><p>85.8 (69.2, 93.8)</p></td><td style="vertical-align:top"><p>60.1 (42.7, 73.7)</p></td></tr><tr><td style="vertical-align:top"><p>Flare-free rate at 12&nbsp;months (95% CI)</p></td><td style="vertical-align:top"><p>76.7 (58.7, 87.6)</p></td><td style="vertical-align:top"><p>54.3 (37.1, 68.7)</p></td></tr><tr><td style="vertical-align:top"><p>Flare-free rate at 18&nbsp;months (95% CI)</p></td><td style="vertical-align:top"><p>73.2 (54.6, 85.1)</p></td><td style="vertical-align:top"><p>42.9 (26.7, 58.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hazard ratio to placebo:</strong> Estimate (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.28 (0.13, 0.63)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stratified log-rank test p-value</strong></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001**</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Analysis was conducted on all randomised patients who received at least one dose of study drug in Part&nbsp;2.</p><p>Secukinumab: all patients who did not take any placebo. Placebo in Part&nbsp;2: all patients who took placebo in Part&nbsp;2 and secukinumab in other period/s. NC = Not calculable. ** = Statistically significant on one-sided significance level 0.025.</p></td></tr></tbody></table><p>&nbsp;</p><p>In open-label Part&nbsp;1, all patients received secukinumab until week&nbsp;12. At week&nbsp;12, 83.7%, 67.4%, and 38.4% of children were JIA ACR 50, 70 and 90 responders, respectively (Figure&nbsp;5). The onset of action of secukinumab occurred as early as week&nbsp;1. At week&nbsp;12 the JADAS-27 score was 4.64 (SD:4.73) and the mean decrease from baseline in JADAS-27 was -10.487 (SD:7.23).</p><p><strong>Figure&nbsp;5</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>JIA ACR 30/50/70/90 response for subjects up to week&nbsp;12 in Part&nbsp;1*</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="794" height="433" vspace="0" hspace="0" border="0" style="width:794px;height:433px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>The data in the 2 to &lt;6 age group were inconclusive due to the low number of patients below 6&nbsp;years of age enrolled in the study.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Cosentyx in plaque psoriasis in paediatric patients aged from birth to less than 6&nbsp;years and in chronic idiopathic arthritis for paediatric patients aged from birth to less than 2&nbsp;years (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Most pharmacokinetics properties observed in patients with plaque psoriasis, psoriatic arthritis and ankylosing spondylitis were similar.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following a single subcutaneous dose of 300&nbsp;mg as a liquid formulation in healthy volunteers, secukinumab reached peak serum concentrations of 43.2&plusmn;10.4&nbsp;&mu;g/ml between 2 and 14&nbsp;days post dose.</p><p>&nbsp;</p><p>Based on population pharmacokinetic analysis, following a single subcutaneous dose of either 150&nbsp;mg or 300&nbsp;mg in plaque psoriasis patients, secukinumab reached peak serum concentrations of 13.7&plusmn;4.8&nbsp;&micro;g/ml or 27.3&plusmn;9.5&nbsp;&micro;g/ml, respectively, between 5 and 6&nbsp;days post dose.</p><p>&nbsp;</p><p>After initial weekly dosing during the first month, time to reach the maximum concentration was between 31 and 34&nbsp;days based on population pharmacokinetic analysis.</p><p>&nbsp;</p><p>On the basis of simulated data, peak concentrations at steady‑state (C<sub>max,ss</sub>) following subcutaneous administration of 150&nbsp;mg or 300&nbsp;mg were 27.6&nbsp;&micro;g/ml and 55.2&nbsp;&micro;g/ml, respectively. Population pharmacokinetic analysis suggests that steady‑state is reached after 20&nbsp;weeks with monthly dosing regimens.</p><p>&nbsp;</p><p>Compared with exposure after a single dose, the population pharmacokinetic analysis showed that patients exhibited a 2‑fold increase in peak serum concentrations and area under the curve (AUC) following repeated monthly dosing during maintenance.</p><p>&nbsp;</p><p>Population pharmacokinetic analysis showed that secukinumab was absorbed with an average absolute bioavailability of 73% in patients with plaque psoriasis. Across studies, absolute bioavailabilities in the range between 60 and 77% were calculated.</p><p>&nbsp;</p><p>The bioavailability of secukinumab in PsA patients was 85% on the basis of the population pharmacokinetic model.</p><p>&nbsp;</p><p>Following a single subcutaneous injection of 300&nbsp;mg solution for injection in pre-filled syringe in plaque psoriasis patients, secukinumab systemic exposure was similar to what was observed previously with two injections of 150&nbsp;mg.</p><p>&nbsp;</p><p>Following subcutaneous administration of 300&nbsp;mg at weeks&nbsp;0, 1, 2, 3 and 4 followed by 300&nbsp;mg every 2&nbsp;weeks, the mean &plusmn; SD steady‑state secukinumab trough concentration at week&nbsp;16 was approximately 55.1&plusmn;26.7&nbsp;&micro;g/ml and 58.1&plusmn;30.1&nbsp;&micro;g/ml in HS study&nbsp;1 and HS study&nbsp;2, respectively.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The mean volume of distribution during the terminal phase (V<sub>z</sub>) following single intravenous administration ranged from 7.10 to 8.60&nbsp;litres in plaque psoriasis patients, suggesting that secukinumab undergoes limited distribution to peripheral compartments.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>The majority of IgG elimination occurs via intracellular catabolism, following fluid‑phase or receptor mediated endocytosis.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Mean systemic clearance (CL) following a single intravenous administration to patients with plaque psoriasis ranged from 0.13 to 0.36&nbsp;l/day. In a population pharmacokinetic analysis, the mean systemic clearance (CL) was 0.19&nbsp;l/day in plaque psoriasis patients. The CL was not impacted by gender. Clearance was dose‑ and time‑independent.</p><p>&nbsp;</p><p>The mean elimination half‑life, as estimated from population pharmacokinetic analysis, was 27&nbsp;days in plaque psoriasis patients, ranging from 18 to 46&nbsp;days across psoriasis studies with intravenous administration.</p><p>&nbsp;</p><p>In a population pharmacokinetic analysis, the mean systemic CL following subcutaneous administration of 300&nbsp;mg at weeks&nbsp;0, 1, 2, 3, and 4 followed by 300&nbsp;mg every 2&nbsp;weeks to patients with hidradenitis suppurativa was 0.26&nbsp;l/day.</p><p>&nbsp;</p><p>The mean elimination half-life, as estimated from population pharmacokinetic analysis, was 23&nbsp;days in hidradenitis suppurativa patients.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>&nbsp;</p><p>The single and multiple dose pharmacokinetics of secukinumab in plaque psoriasis patients were determined in several studies with intravenous doses ranging from 1x 0.3&nbsp;mg/kg to 3x 10&nbsp;mg/kg and with subcutaneous doses ranging from 1x 25&nbsp;mg to multiple doses of 300&nbsp;mg. Exposure was dose proportional across all dosing regimens.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly patients</u></em></p><p>Based on population pharmacokinetic analysis with a limited number of elderly patients (n=71 for age &ge;65&nbsp;years and n=7 for age &ge;75&nbsp;years), clearance in elderly patients and patients less than 65&nbsp;years of age was similar.</p><p>&nbsp;</p><p><em><u>Patients with renal or hepatic impairment</u></em></p><p>No pharmacokinetic data are available in patients with renal or hepatic impairment. The renal elimination of intact secukinumab, an IgG monoclonal antibody, is expected to be low and of minor importance. IgGs are mainly eliminated via catabolism and hepatic impairment is not expected to influence clearance of secukinumab.</p><p>&nbsp;</p><p><em><u>Effect of weight on pharmacokinetics</u></em></p><p>Secukinumab clearance and volume of distribution increase as body weight increases.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><em>Plaque psoriasis</em></p><p>In a pool of the two paediatric studies, patients with moderate to severe plaque psoriasis (6 to less than 18&nbsp;years of age) were administered secukinumab at the recommended paediatric dosing regimen. At week&nbsp;24, patients weighing &ge;25 and &lt;50&nbsp;kg had a mean &plusmn; SD steady-state trough concentration of 19.8&nbsp;&plusmn;&nbsp;6.96&nbsp;&micro;g/ml (n=24) after 75&nbsp;mg of secukinumab and patients weighing &ge;50&nbsp;kg had mean &plusmn;SD trough concentration of 27.3&nbsp;&plusmn;&nbsp;10.1&nbsp;&micro;g/ml (n=36) after 150&nbsp;mg of secukinumab. The mean &plusmn; SD steady-state trough concentration in patients weighing &lt;25&nbsp;kg (n=8) was 32.6&nbsp;&plusmn;&nbsp;10.8&nbsp;&micro;g/ml at week&nbsp;24 after 75&nbsp;mg dose.</p><p>&nbsp;</p><p><em>Juvenile idiopathic arthritis</em></p><p>In a paediatric study, ERA and JPsA patients (2 to less than 18&nbsp;years of age) were administered secukinumab at the recommended paediatric dosing regimen. At week&nbsp;24, patients weighing &lt;50&nbsp;kg, and weighing &ge;50&nbsp;kg had a mean &plusmn; SD steady-state trough concentration of 25.2&plusmn;5.45&nbsp;&micro;g/ml (n=10) and 27.9&plusmn;9.57&nbsp;&micro;g/ml (n=19), respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data revealed no special hazard for humans (adult or paediatric) based on conventional studies of safety pharmacology, repeated dose and reproductive toxicity, or tissue cross‑reactivity.</p><p>&nbsp;</p><p>Animal studies have not been conducted to evaluate the carcinogenic potential of secukinumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trehalose dihydrate</p><p>Histidine</p><p>Histidine hydrochloride monohydrate</p><p>Methionine</p><p>Polysorbate 80</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
If necessary, Cosentyx may be stored unrefrigerated for a single period of up to 4 days at room temperature, not above 30°C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C). Do not freeze.</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cosentyx 150&nbsp;mg solution for injection in pre-filled syringe</u></p><p><u>&nbsp;</u></p><p>Cosentyx 150&nbsp;mg solution for injection in pre-filled syringe is supplied in a pre‑filled 1&nbsp;ml glass syringe with a silicone‑coated bromobutyl rubber plunger stopper, staked 27G&nbsp;x&nbsp;&frac12;&Prime; needle and rigid needle shield of styrene butadiene rubber assembled in an automatic needle guard of polycarbonate.</p><p>&nbsp;</p><p>Cosentyx 150&nbsp;mg solution for injection in pre-filled syringe is available in unit packs containing 1 or 2&nbsp;pre‑filled syringes and in multipacks containing 6&nbsp;(3&nbsp;packs of 2) pre-filled syringes.</p><p>&nbsp;</p><p><u>Cosentyx 300&nbsp;mg solution for injection in pre-filled syringe</u></p><p><u>&nbsp;</u></p><p>Cosentyx 300&nbsp;mg solution for injection in pre-filled syringe is supplied in a pre‑filled 2.25&nbsp;ml glass syringe with a silicone‑coated bromobutyl rubber plunger stopper, staked 27G&nbsp;x&nbsp;&frac12;&Prime; needle and rigid needle shield of synthetic polyisoprene rubber assembled in an automatic needle guard of polycarbonate.</p><p>&nbsp;</p><p>Cosentyx 300&nbsp;mg solution for injection in pre-filled syringe is available in unit packs containing 1&nbsp;pre‑filled syringe and in multipacks containing 3&nbsp;(3&nbsp;packs of 1) pre-filled syringes.</p><p>&nbsp;</p><p><u>Cosentyx 150&nbsp;mg solution for injection in pre-filled pen</u></p><p>&nbsp;</p><p>Cosentyx 150&nbsp;mg solution for injection in pre-filled pen is supplied in a single‑use pre‑filled syringe</p><p>assembled into a triangular‑shaped pen with transparent window and label. The pre‑filled syringe inside the pen is a 1&nbsp;ml glass syringe with a silicone‑coated bromobutyl rubber plunger stopper, staked 27G&nbsp;x&nbsp;&frac12;&Prime; needle and rigid needle shield of styrene butadiene rubber.</p><p>&nbsp;</p><p>Cosentyx 150&nbsp;mg solution for injection in pre-filled pen is available in unit packs containing 1 or 2&nbsp;pre‑filled pens and in multipacks containing 6&nbsp;(3&nbsp;packs of 2) pre-filled pens.</p><p>&nbsp;</p><p><u>Cosentyx 300&nbsp;mg solution for injection in pre-filled pen</u></p><p><u>&nbsp;</u></p><p>Cosentyx 300&nbsp;mg solution for injection in pre-filled pen is supplied in a single‑use pre‑filled syringe assembled into a squared‑shaped pen with transparent window and label. The pre‑filled syringe inside the pen is a 2.25&nbsp;ml glass syringe with a silicone‑coated bromobutyl rubber plunger stopper, staked 27G&nbsp;x&nbsp;&frac12;&Prime; needle and rigid needle shield of synthetic polyisoprene rubber.</p><p>&nbsp;</p><p>Cosentyx 300&nbsp;mg solution for injection in pre-filled pen is available in unit packs containing 1&nbsp;pre‑filled pen and in multipacks containing 3&nbsp;(3&nbsp;packs of 1) pre-filled pens.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cosentyx 150&nbsp;mg solution for injection in pre-filled syringe</u></p><p><u>&nbsp;</u></p><p>Cosentyx 150&nbsp;mg solution for injection is supplied in a single‑use pre‑filled syringe for individual use. The syringe should be taken out of the refrigerator 20&nbsp;minutes before injecting to allow it to reach room temperature.</p><p>&nbsp;</p><p><u>Cosentyx 300&nbsp;mg solution for injection in pre-filled syringe</u></p><p><u>&nbsp;</u></p><p>Cosentyx 300&nbsp;mg solution for injection is supplied in a single‑use pre‑filled syringe for individual use. The syringe should be taken out of the refrigerator 30‑45&nbsp;minutes before injecting to allow it to reach room temperature.</p><p>&nbsp;</p><p><u>Cosentyx 150&nbsp;mg solution for injection in pre-filled pen</u></p><p>&nbsp;</p><p>Cosentyx 150&nbsp;mg solution for injection is supplied in a single‑use pre‑filled pen for individual use. The pen should be taken out of the refrigerator 20&nbsp;minutes before injecting to allow it to reach room temperature.</p><p>&nbsp;</p><p><u>Cosentyx 300&nbsp;mg solution for injection in pre-filled pen</u></p><p><u>&nbsp;</u></p><p>Cosentyx 300&nbsp;mg solution for injection is supplied in a single‑use pre‑filled pen for individual use. The pen should be taken out of the refrigerator 30‑45&nbsp;minutes before injecting to allow it to reach room temperature.</p><p>&nbsp;</p><p>Prior to use, a visual inspection of the pre‑filled syringe or pre-filled pen is recommended. The liquid should be clear. Its colour may vary from colourless to slightly yellow. You may see a small air bubble, which is normal. Do not use if the liquid contains easily visible particles, is cloudy or is distinctly brown.</p><p>Detailed instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local&nbsp;requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>